<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Arch Virol</journal-id><journal-id journal-id-type="iso-abbrev">Arch Virol</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Archives of Virology</journal-title></journal-title-group><issn pub-type="ppub">0304-8608</issn><issn pub-type="epub">1432-8798</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8363864</article-id><article-id pub-id-type="pmcid-ver">PMC8363864.1</article-id><article-id pub-id-type="pmcaid">8363864</article-id><article-id pub-id-type="pmcaiid">8363864</article-id><article-id pub-id-type="pmid">34390393</article-id><article-id pub-id-type="doi">10.1007/s00705-021-05158-z</article-id><article-id pub-id-type="publisher-id">5158</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>New insights into pathogenesis point to HIV-1 Tat as a key vaccine target</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0545-8737</contrib-id><name name-style="western"><surname>Ensoli</surname><given-names initials="B">Barbara</given-names></name><address><email>barbara.ensoli@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moretti</surname><given-names initials="S">Sonia</given-names></name><address><email>sonia.moretti@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Borsetti</surname><given-names initials="A">Alessandra</given-names></name><address><email>alessandra.borsetti@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maggiorella</surname><given-names initials="MT">Maria Teresa</given-names></name><address><email>mariateresa.maggiorella@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Butt&#242;</surname><given-names initials="S">Stefano</given-names></name><address><email>stefano.butto@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Picconi</surname><given-names initials="O">Orietta</given-names></name><address><email>orietta.picconi@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tripiciano</surname><given-names initials="A">Antonella</given-names></name><address><email>antonella.tripiciano@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sgadari</surname><given-names initials="C">Cecilia</given-names></name><address><email>cecilia.sgadari@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Monini</surname><given-names initials="P">Paolo</given-names></name><address><email>paolo.monini@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cafaro</surname><given-names initials="A">Aurelio</given-names></name><address><email>aurelio.cafaro@iss.it</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.416651.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9120 6856</institution-id><institution>National HIV/AIDS Research Center, Istituto Superiore di Sanit&#224;, </institution></institution-wrap>Viale Regina Elena 299, 00161 Rome, Italy </aff></contrib-group><author-notes><fn fn-type="com"><p>Handling Editor: Marc H. V. Van Regenmortel.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2021</year></pub-date><pub-date pub-type="ppub"><year>2021</year></pub-date><volume>166</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">387982</issue-id><fpage>2955</fpage><lpage>2974</lpage><history><date date-type="received"><day>14</day><month>1</month><year>2021</year></date><date date-type="accepted"><day>9</day><month>5</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>08</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>15</day><month>08</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-09 20:25:41.610"><day>09</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2021</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="705_2021_Article_5158.pdf"/><abstract id="Abs1"><p id="Par1">Despite over 30 years of enormous effort and progress in the field, no preventative and/or therapeutic vaccines against human immunodeficiency virus (HIV) are available. Here, we briefly summarize the vaccine strategies and vaccine candidates that in recent years advanced to efficacy trials with mostly unsatisfactory results. Next, we discuss a novel and somewhat contrarian approach based on biological and epidemiological evidence, which led us to choose the HIV protein Tat for the development of preventive and therapeutic HIV vaccines. Toward this goal, we review here the role of Tat in the virus life cycle as well as experimental and epidemiological evidence supporting its key role in the natural history of HIV infection and comorbidities. We then discuss the preclinical and clinical development of a Tat therapeutic vaccine, which, by improving the functionality and homeostasis of the immune system and by reducing the viral reservoir in virologically suppressed vaccinees, helps to establish key determinants for intensification of combination antiretroviral therapy (cART) and a functional cure. Future developments and potential applications of the Tat therapeutic vaccine are also discussed, as well as the rationale for its use in preventative strategies. We hope this contribution will lead to a reconsideration of the current paradigms for the development of HIV/AIDS vaccines, with a focus on targeting of viral proteins with key roles in HIV pathogenesis.</p></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006601</institution-id><institution>Ministero degli Affari Esteri e della Cooperazione Internazionale</institution></institution-wrap></funding-source><award-id>AID 8421</award-id><principal-award-recipient><name name-style="western"><surname>Ensoli</surname><given-names>Barbara</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003196</institution-id><institution>Ministero della Salute</institution></institution-wrap></funding-source><award-id>Special project on the Development of a Vaccine against HIV based on the Tat protein</award-id><award-id>RF-2011-02348970</award-id><award-id>RF-2016-02364744</award-id><award-id>Ricerca Corrente 2020</award-id><principal-award-recipient><name name-style="western"><surname>Ensoli</surname><given-names>Barbara</given-names></name><name name-style="western"><surname>Monini</surname><given-names>Paolo</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>Aurelio</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Austria, part of Springer Nature 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><sec id="Sec2"><title>Exploring vaccine development strategies and predicting vaccine efficacy</title><p id="Par2">The human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic is still a major global health challenge, with 38.0 million people living with HIV (PLWH) in 2019, and 1.7 million newly infected (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2020/july/20200706_global-aids-report">https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2020/july/20200706_global-aids-report</ext-link>). Thus, there is an urgent need to implement effective strategies to prevent and cure HIV infection and reduce virus transmission [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p id="Par3">Although combination antiretroviral therapy (cART) is effective in suppressing the virus and reducing mortality, it does not eradicate HIV, which invariably rebounds upon suspension of treatment due to virus release by a small pool of long-lived cells harboring latent provirus, which are insensitive to cART and invisible to the immune system [<xref ref-type="bibr" rid="CR2">2</xref>]. This hampers cART effectiveness in containing HIV transmission and spread [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par4">Furthermore, despite great efforts and major advancements in our understanding of HIV pathogenesis and in vaccine development, effective vaccines against HIV/AIDS are still lacking.</p><p id="Par5">The challenges for developing a vaccine against HIV stem from (i) the high rate of intra- and inter-individual HIV genetic evolution, leading to the unceasing emergence of new (escape) variants, (ii) the failure to identify strong and unequivocal correlates of protection in studies of natural infection as well as in vaccine studies, and (iii) the knowledge gap regarding the degree of protection conferred by the immune response to antigenic epitopes present in the transmitted/founder viruses versus viral variants emerging during chronic infection.</p><p id="Par6">The first vaccine candidates largely focused on the glycoproteins of the virus envelope, which mediate the attachment and entry of HIV into the cell (gp120 or gp160) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. AIDSVAX was the first of the Env-based vaccines to be tested in efficacy trials (VAX 003, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00006327">NCT 00006327</ext-link> and VAX 004, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00002441">NCT 00002441</ext-link>). However, AIDSVAX failed to induce a protective, neutralizing humoral response, most likely due to the high variability of Env in the circulating virus variants [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. These failures shifted the focus to cell-mediated immunity, owing to an accumulating body of evidence indicating a major role for CD8<sup>+</sup> T cells in controlling HIV infection [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. Vaccines aimed at inducing effective cellular responses were based on live recombinant viral vectors, mainly pox and adenovirus vectors, and/or DNA consisting of the <italic toggle="yes">gag, pol</italic>, and <italic toggle="yes">nef</italic> genes from clade B or clade C HIV, with or without Env [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Although all approaches induced measurable cell-mediated immune responses, they had to be halted due to the greater number of HIV-1 infections occurring in vaccinees as compared to placebo, as observed in the STEP (HVTN 502, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00095576">NCT00095576</ext-link>) and Phambili (HVTN 503, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00413725">NCT 00413725</ext-link>) trials, or they did not show efficacy (HVTN 505, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00865566">NCT00865566</ext-link>) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR19">19</xref>]. The vectors used to deliver the HIV proteins are believed to have contributed to vaccine failure [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par7">Expectations were then raised by the RV144 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00223080">NCT00223080</ext-link>) trial utilizing a recombinant canarypox vector expressing Env from clade E and Gag and the HIV protease from clade B HIV (the ALVAC-HIV vCP1521 vaccine antigen component), followed by a boost with an alum-adjuvanted subunit HIV gp120 from clades B and E (the AIDSVAX B/E vaccine antigen component). The vaccine induced a humoral immune response against gp120 and antibody-dependent cellular cytotoxicity that was able to confer protection from infection in 31.2% of the vaccinated volunteers [<xref ref-type="bibr" rid="CR21">21</xref>], leading to the design of the HVTN 702 trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02968849">NCT 02968849</ext-link>) conducted in South Africa, which, however, did not show efficacy (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/news-events/experimental-hiv-vaccine-regimen-ineffective-preventing-hiv">https://www.niaid.nih.gov/news-events/experimental-hiv-vaccine-regimen-ineffective-preventing-hiv</ext-link>).</p><p id="Par8">Concurrently, major efforts and resources were devoted to the isolation and characterization of broadly neutralizing antibodies (bNAbs) from infected patients [<xref ref-type="bibr" rid="CR22">22</xref>]. It turned out that, in general, bNAbs have a very uncommon structure, are often polyreactive and autoreactive, possibly the result of escape from immune selection of the B cell repertoire, as also suggested by the lack of germline precursors in the B cell repertoire [<xref ref-type="bibr" rid="CR23">23</xref>]. Accordingly, immunogens structurally designed to optimally bind bNAbs failed to induce them <italic toggle="yes">in vivo</italic> [<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>]. These obstacles are so difficult to overcome [<xref ref-type="bibr" rid="CR27">27</xref>] that the efficacy of bNAbs is presently being evaluated in passive immunization strategies [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par9">More recently, a computational methodology was developed to generate polyvalent mosaic immunogens starting from the sequences of naturally occurring variants of common T cell epitopes that may ensure coverage of HIV diversity [<xref ref-type="bibr" rid="CR29">29</xref>]. An example of this &#8220;mosaic&#8221; approach is the Ad26/Ad26 plus gp140 HIV-1 vaccine, which was recently shown to induce robust humoral and cellular immune responses in a phase 1/2a clinical trial, and it is being evaluated in a phase 2b efficacy study in sub-Saharan Africa&#160;(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03060629">NCT03060629</ext-link>).</p><p id="Par10">Efforts have also been directed to optimization of analysis of vaccine trial results with the aim of identifying correlates of protection. Among these, the COMPASS (Computerized Optimization Model for Predicting and Analyzing Support Scenarios) analysis, a bioinformatics tool to identify antigen-specific T cell responses and subsets, was recently used to investigate vaccine-induced immune responses leading to the identification of new &#8220;correlates of protection/immunity&#8221; previously missed in the RV144 HIV vaccine efficacy trial [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par11">Failures in HIV preventative and therapeutic vaccine strategies have led us to focus on alternative strategies using a &#8220;pathogenetic&#8221; approach aimed at targeting the HIV Tat protein, alone or combined with other HIV antigens, for eliciting protective immunity for preventative and therapeutic vaccination of untreated or cART-treated patients.</p></sec></sec><sec id="Sec3"><title>Tat and HIV pathogenesis</title><sec id="Sec4"><title>Role of Tat in the virus life cycle</title><sec id="Sec5"><title>Tat-mediated effects on HIV-1 infectivity, replication, and transmission</title><p id="Par12">The HIV Tat protein is a potent transcriptional transactivator of virus gene expression that is essential for virus infectivity, replication, and transmission (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Tat is incorporated into HIV-1 virions [<xref ref-type="bibr" rid="CR32">32</xref>] to prime both endogenous (intra-virion) and post-entry reverse transcription [<xref ref-type="bibr" rid="CR33">33</xref>], to activate virus gene expression, and to form a complex with HIV-1 Env to enhance virus entry and spread [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Roles of extracellular Tat in HIV in virus life cycle and in the latent virus reservoir. <bold>A</bold> Stochastic oscillations of HIV-1 Tat protein expression (the Tat stochastic switch) determine the fate of HIV infection [<xref ref-type="bibr" rid="CR40">40</xref>]; <bold>B</bold> Membrane-bond extracellular Tat induces CTL apoptosis [<xref ref-type="bibr" rid="CR64">64</xref>]; <bold>C</bold> Extracellular Tat binds Env to form a HIV entry complex [<xref ref-type="bibr" rid="CR35">35</xref>] that increases virus infectivity and the HIV basic reproduction number (R<sub>0</sub>), thus increasing the chances of infection in tissue compartments with low-drug penetration; at the same time, extracellular Tat induces in na&#239;ve CD4+ T cells a non-classical activation pathway rendering these cells susceptible to HIV infection [<xref ref-type="bibr" rid="CR54">54</xref>]; <bold>D</bold> Extracellular Tat enhances the expansion and differentiation of na&#239;ve CD4+ T cells into effector-memory cells [<xref ref-type="bibr" rid="CR75">75</xref>], thus increasing the number of cells transitioning from the activated to the resting state, a cell state that favors latent infection [<xref ref-type="bibr" rid="CR94">94</xref>]; <bold>E</bold> Extracellular Tat forms chemotactic gradients [<xref ref-type="bibr" rid="CR46">46</xref>; <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] recruiting monocytes/macrophages and dendritic cells to the site of infection (51), induces the release of pro-inflammatory cytokines [<xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR63">63</xref>] and the maturation of dendritic cells with a Th-1 polarization [<xref ref-type="bibr" rid="CR52">52</xref>]; <bold>F</bold> Tat upregulates BCL2 in CD4+ T cells, leading to increased reservoir cell survival [<xref ref-type="bibr" rid="CR93">93</xref>] while rendering these cells resistant to CTL killing [<xref ref-type="bibr" rid="CR94">94</xref>]</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="705_2021_5158_Fig1_HTML.jpg"/></fig></p><p id="Par13">Tat is expressed very early upon infection, even prior to virus integration [<xref ref-type="bibr" rid="CR36">36</xref>], most likely to ensure that the transcriptional activity of the incoming virus can cross the extinction threshold. Tat expression, in fact, enhances both transcription initiation, which is mediated by its interaction with SP1 elements in the HIV-1 transcriptional promoter [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], and transcription elongation, which involves Tat-mediated recruitment of positive transcription elongation factor b (P-TEFb) to the transactivation responsive region (TAR) of the nascent RNA [<xref ref-type="bibr" rid="CR39">39</xref>]. By these means, Tat increases viral transcription by 100-fold and establishes a strong positive transcriptional feedback loop at the HIV-1 long terminal repeat (LTR) [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Notably, the early expression of Tat appears to enhance, rather than stabilize, basal transcriptional fluctuations that occur naturally at the HIV LTR. As a consequence, Tat expression itself is driven into amplified stochastic oscillations around the extinction threshold [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. As described in the next section, this pattern of Tat expression plays a major role in determining whether infected cells enter a state of active replication or latency [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. In addition to these activities, Tat expression downregulates cell membrane expression of major histocompatibility complex (MHC) class I [<xref ref-type="bibr" rid="CR42">42</xref>] and II [<xref ref-type="bibr" rid="CR43">43</xref>] surface molecules, damping cell-mediated adaptive immunity against HIV. Moreover, in infected dendritic cells (DCs), Tat induces the expression of several chemokines, including interferon-gamma-induced protein 10 (IP-10, CXCL10), human monokine induced by interferon gamma (huMIG, CXCL9), and monocyte chemotactic protein 2 (MCP-2, CCL8), attracting activated T cells and macrophages to the sites of infection, thus facilitating the dissemination of HIV infection [<xref ref-type="bibr" rid="CR44">44</xref>].</p></sec><sec id="Sec6"><title>Role of extracellular Tat in HIV-1 infectivity and virus spread</title><p id="Par14">A large proportion of the Tat protein produced by the infected cell is released in the absence of cell death or cell permeability changes in the extracellular milieu [<xref ref-type="bibr" rid="CR45">45</xref>&#8211;<xref ref-type="bibr" rid="CR47">47</xref>] to generate a local reservoir of extracellular Tat, which plays a key role in the establishment and propagation of HIV infection. In fact, once released, Tat binds through its basic region to heparan sulfate proteoglycans (HSPG) present in the extracellular matrix [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>], generating long-lasting chemotactic gradients that attract HIV-1 target cells, particularly, activated endothelial cells and monocytes/macrophages, to the sites of infection [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. In addition, extracellular Tat enters dendritic cells [<xref ref-type="bibr" rid="CR52">52</xref>] and activated endothelial cells [<xref ref-type="bibr" rid="CR53">53</xref>] very efficiently and, to a lesser extent, CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR54">54</xref>], activating the expression of genes favoring HIV dissemination. In particular, in na&#239;ve CD4<sup>+</sup> T cells, Tat upregulates the expression of the HIV-1 co-receptors C-X-C motif chemokine receptor 4 (CXCR4) and C-C chemokine receptor type 5 (CCR5) [<xref ref-type="bibr" rid="CR55">55</xref>], while antagonizing CXCR4 [<xref ref-type="bibr" rid="CR56">56</xref>], thus increasing the susceptibility of resting CD4<sup>+</sup> T cells to infection by R5-tropic HIV-1 strains. Furthermore, extracellular Tat induces a non-classical activation pathway in na&#239;ve CD4<sup>+</sup> T cells, rendering them susceptible to productive infection [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Notably, extracellular Tat binds trimeric HIV-1 Env, forming a cell entry complex (the Tat/Env complex) that targets the RGD-binding integrins expressed at high levels by dendritic cells, enhancing the infection of these cells [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Furthermore, extracellular Tat induces dendritic cells to mature to a T helper (Th)-1-polarizing phenotype [<xref ref-type="bibr" rid="CR58">58</xref>] and stimulates the production and release of inflammatory cytokines by various cell types [<xref ref-type="bibr" rid="CR59">59</xref>&#8211;<xref ref-type="bibr" rid="CR63">63</xref>]. Of note, inflammatory cytokines activate endothelial cells and render them susceptible to Tat entry and permissive to productive HIV infection [<xref ref-type="bibr" rid="CR53">53</xref>]. In addition, extracellular Tat bound to the HSPG of the infected cell membrane triggers the apoptotic death of engaged CD8<sup>+</sup> T cell effectors [<xref ref-type="bibr" rid="CR64">64</xref>]. Thus, extracellular Tat contributes to modeling a tissue microenvironment favoring the recruitment, infection, and immune escape of HIV-1 target cells. All of these activities of extracellular Tat contribute to ensuring that the basic reproduction number (R<sub>0</sub>) of HIV remains &gt; 1 both upon virus acquisition at the portal of entry and during chronic infection.</p></sec><sec id="Sec7"><title>Role of the Tat feedback transcriptional loop in the &#8220;choice&#8221; between latent and active infection</title><p id="Par15">HIV-1 infection is characterized by the early establishment of a self-renewing, large pool of short-lived, actively infected cells producing viral progeny. However, concomitant latent infection occurs in a minority of cells that show prolonged longevity and are maintained for a long period of time. As described previously, the choice between productive and latent infection of CD4<sup>+</sup> T cells appears to be determined by stochastic oscillations in the expression levels of Tat around the threshold of viral transcriptional extinction [<xref ref-type="bibr" rid="CR41">41</xref>]. This modality of Tat expression (the &#8220;Tat stochastic switch&#8221;) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) appears to operate irrespectively of the state of cell activation [<xref ref-type="bibr" rid="CR41">41</xref>]. Nevertheless, the activation or deactivation of the HIV-1 transcriptional promoter by environmental or epigenetic stimuli can increase or decrease the probability ratio between latent and active infection [<xref ref-type="bibr" rid="CR41">41</xref>]. The Tat stochastic switch likely explains several characteristic features of HIV infection both <italic toggle="yes">in vitro</italic> and in clinical studies. In particular: (i) distinct pools of latently and productively infected cells are simultaneously established upon experimental infection of activated or resting CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR65">65</xref>&#8211;<xref ref-type="bibr" rid="CR67">67</xref>]; (ii) clonal CD4<sup>+</sup> T cell populations harboring the same provirus at the same integration site show a &#8216;bifurcating&#8217; expression pattern, where HIV expression is high in some cells and low in others [<xref ref-type="bibr" rid="CR40">40</xref>]; (iii) polyclonal TCR stimulators stochastically reactivate HIV in only a small number of cells in the latently infected pool present in cultures of CD4<sup>+</sup> T cells isolated from HIV-infected patients [<xref ref-type="bibr" rid="CR68">68</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]; (iv) a spontaneous fluctuation between a latent and productive infection phenotype is observed in clonal cultures of infected CD4<sup>+</sup> T cell lines [<xref ref-type="bibr" rid="CR40">40</xref>]; (v) virus rebound in patients undergoing analytical treatment interruption follows a stochastic, exponential distribution [<xref ref-type="bibr" rid="CR70">70</xref>]; (vi) the &#8220;shock and kill&#8221; strategy to cure HIV, based on the use of HIV latency-reversing agents believed to deterministically reactivate latent HIV, has failed to reduce the HIV reservoirs [<xref ref-type="bibr" rid="CR71">71</xref>]; and (vii) HIV reactivation in latently infected CD4<sup>+</sup> T cells is virtually abolished by treatment with compounds that block the interaction of Tat with TAR, a finding that has led to the development of strategies to permanently shut off HIV transcription (the &#8220;block and lock&#8221; strategy) [<xref ref-type="bibr" rid="CR72">72</xref>].</p></sec><sec id="Sec8"><title>Role of extracellular Tat in the dynamics of latent HIV reservoirs</title><p id="Par16">The small pool of long-lived cells harboring latent HIV persists indefinitely in infected individuals despite cART. Sporadic reactivation of latent provirus results in waves of virus production that, although it may not succeed in infecting other cells due to antiretroviral treatment, can give rise to intermittent low-level viremia that persists even after years of treatment [<xref ref-type="bibr" rid="CR73">73</xref>]; if cART is suspended, low-level viremia leads to virus rebound [<xref ref-type="bibr" rid="CR74">74</xref>]. Although several cell types can harbor latent or silent HIV, resting na&#239;ve and memory CD4<sup>+</sup> T cells constitute the most prominent HIV reservoir [<xref ref-type="bibr" rid="CR73">73</xref>]. Considering the capability of extracellular Tat to target and enter CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR54">54</xref>], to stimulate the expression of host cell genes [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR75">75</xref>], and to reactivate latent provirus [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR76">76</xref>], it can be speculated that extracellular Tat plays a prominent role in the dynamics of HIV reservoirs. This conclusion is supported by the faster kinetics of proviral DNA decay observed in individuals on long-term cART immunized with a Tat vaccine [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>], suggesting that immunity against extracellular Tat, the vaccine target, may destabilize the HIV reservoirs. The following lines of evidence point to the possible mechanism(s) underlying this effect of Tat immunization.</p><p id="Par17">Despite lack of evidence of virus evolution during long-term cART [<xref ref-type="bibr" rid="CR79">79</xref>&#8211;<xref ref-type="bibr" rid="CR84">84</xref>], indirect evidence indicates that ongoing cycles of virus replication may indeed occur in low-drug lymphoid tissue compartments, replenishing the HIV reservoirs [<xref ref-type="bibr" rid="CR85">85</xref>&#8211;<xref ref-type="bibr" rid="CR89">89</xref>]. However, HIV reproduction in these infection niches would be prone to extinction due to the reduction of R<sub>0</sub> caused by the suboptimal drug levels of the microenvironment. Hence, the enhancement of infectivity conferred to HIV by the Tat/Env complex, which appears to be particularly effective at a low multiplicity of infection [<xref ref-type="bibr" rid="CR35">35</xref>], would conceivably be of key importance for virus reproduction in these tissues. Since anti-Tat Abs produced during natural infection or induced by Tat immunization neutralize the Tat/Env complex [<xref ref-type="bibr" rid="CR35">35</xref>], these data suggest that immunization with Tat might blunt this potential pathway of reservoir replenishment. CD4<sup>+</sup> T cells undergoing the effector-to-memory transition may be pivotal in this context. These cells have been shown to be particularly susceptible to latent HIV infection due to the transient upregulation of the HIV co-receptor CCR5 and the concomitant downregulation of cellular and proviral gene expression [<xref ref-type="bibr" rid="CR90">90</xref>]. Hence, activated CD4<sup>+</sup> T cells transitioning to the resting state represent a key target to enrich latent-HIV reproduction in compartments with suboptimal drug levels. Since extracellular Tat is known to enhance the expansion and differentiation of na&#239;ve CD4<sup>+</sup> T cells towards the effector-memory phenotype [<xref ref-type="bibr" rid="CR75">75</xref>], we speculate that immunization with Tat may decrease the density of transitioning cells in these tissue niches. Moreover, extracellular Tat delays Fas-mediated apoptosis in infected CD4<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR91">91</xref>] and upregulates the anti-apoptotic gene B-cell lymphoma 2 (Bcl-2) in peripheral blood mononuclear cells (PBMCs) and CD4<sup>+</sup> T cells, as well as endothelial cells [<xref ref-type="bibr" rid="CR92">92</xref>], promoting their survival [<xref ref-type="bibr" rid="CR93">93</xref>]. Notably, recent findings indicate that Bcl-2 upregulation renders reservoir CD4<sup>+</sup> T cells resistant to cytotoxic T lymphocyte (CTL) killing [<xref ref-type="bibr" rid="CR94">94</xref>]. Thus, extracellular Tat may prolong the half-life of latently infected CD4<sup>+</sup> T cells, which, conversely, would be decreased by anti-Tat Abs induced by Tat immunization. Finally, anti-Tat Abs would abrogate the capacity of cell-membrane-bound Tat to induce the apoptosis of CD8<sup>+</sup> T cell effectors [<xref ref-type="bibr" rid="CR64">64</xref>], restoring, at least in part, the effectiveness of cell-mediated immunity against the virus reservoirs.</p><p id="Par18">Figure <xref rid="Fig1" ref-type="fig">1</xref> summarizes the main pathways through which HIV-1 Tat regulates the virus life cycle and the genesis and maintenance of the virus reservoirs.</p></sec></sec><sec id="Sec9"><title>Tat and comorbidities</title><p id="Par19">The experimental and epidemiological data reported above indicate that Tat is an optimal target for HIV cure and eradication strategies. However, a Tat-based therapeutic immunization may have other beneficial effects against HIV/AIDS, since <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> evidence indicates that HIV-1 Tat plays a role in the increased incidence and aggressiveness of several AIDS- and non-AIDS-defining comorbidities, including tumors and cardiovascular, renal, liver and neurological diseases. The development and progression of these comorbidities are attributed to the combined effects of reduced immune surveillance, immune activation, immune dysregulation, and viral coinfections (Epstein-Barr virus [EBV], human herpesvirus 8 [HHV-8], human papillomavirus [HPV], hepatitis B virus, hepatitis C virus) characterizing HIV infection [<xref ref-type="bibr" rid="CR95">95</xref>].</p><p id="Par20">Of note, the introduction of highly effective new antiretrovirals and new drug combinations capable of suppressing viral replication has greatly reduced the burden of most AIDS-related complications by restoring and preserving immune function from the decline associated with HIV infection, with a general increase in quality and expectancy of life [<xref ref-type="bibr" rid="CR96">96</xref>]. However, since cART does not eliminate non-replicating virus, life-long cART is essential for insuring viral suppression. Moreover, even under fully successful therapy, residual viral replication and/or gene transcription persist [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>], particularly in lymphoid tissues with suboptimal antiviral drug penetration [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR99">99</xref>]. As a result, chronic inflammation and immune dysregulation persist, leading to premature aging and a much higher incidence and mortality rate for chronic noninfectious comorbidities as compared to the general population, particularly in patients starting cART with very low CD4<sup>+</sup> T cell counts or in those who are poorly compliant with therapy [<xref ref-type="bibr" rid="CR96">96</xref>]. An increased life expectancy, longer exposure to risk factors, and drug toxicity also correlate with the appearance of non AIDS-related comorbidities. However, although cART reduces the risk for AIDS-defining comorbidities, including tumors and opportunistic infections, their incidence is still higher than in the general population and can also occur in patients responding to therapy [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR100">100</xref>].</p><p id="Par21">In this context, experimental evidence indicates that HIV-1 Tat may play a direct pathogenetic role in HIV-associated comorbidities by modulating the cellular pathways that lead to their development and/or progression. Although a comprehensive examination of these data is outside of the scope of this review, some of these direct effects are briefly described below and summarized in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Evidence indicating that the HIV-1 Tat protein is directly involved in the increased incidence and severity of comorbidities and coinfections affecting PLWH</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Direct effects of Tat</th><th align="left" colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">AIDS-associated tumors</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="6" colspan="1">Kaposi&#8217;s sarcoma</td><td align="left" colspan="1" rowspan="1">Proliferation, migration and invasion of KS cells</td><td align="left" rowspan="6" colspan="1">[<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR101">101</xref>&#8211;<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Recruitment of HHV-8-infected circulating KS cells; HHV-8 reactivation from latency; increase of tumor progression induced by HHV-8-encoded oncoproteins</td></tr><tr><td align="left" colspan="1" rowspan="1">Induction of inflammatory cytokines/adhesion marker expression in endothelial cells and KS cells</td></tr><tr><td align="left" colspan="1" rowspan="1">Induction of inflammatory cell adhesion and extravasation</td></tr><tr><td align="left" colspan="1" rowspan="1">Induction of angiogenesis and vascular permeability in synergy with bFGF or inflammatory cytokines, by activating MMPs and cell-cycle progression in endothelial cells</td></tr><tr><td align="left" colspan="1" rowspan="1">Increased survival by promoting Bcl-2 expression in endothelial cells</td></tr><tr><td align="left" rowspan="3" colspan="1">Cervical carcinoma</td><td align="left" colspan="1" rowspan="1">Disruption of epithelial tight junctions and HPV entry into epithelium by activation of integrin and MAPK signaling</td><td align="left" rowspan="3" colspan="1">[<xref ref-type="bibr" rid="CR111">111</xref>&#8211;<xref ref-type="bibr" rid="CR116">116</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Transactivation of the HPV long control region and increase of HPV-E7 expression</td></tr><tr><td align="left" colspan="1" rowspan="1">Upregulation of HPV-E6 expression and decrease of p53 protein levels</td></tr><tr><td align="left" rowspan="4" colspan="1">Lymphoproliferative disorders</td><td align="left" colspan="1" rowspan="1">Enhancement of EBV-driven B cell proliferation</td><td align="left" rowspan="4" colspan="1">[<xref ref-type="bibr" rid="CR117">117</xref>&#8211;<xref ref-type="bibr" rid="CR122">122</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Induction of mutagenic DNA repair h-polymerase</td></tr><tr><td align="left" colspan="1" rowspan="1">Repositioning of the MYC locus near the immunoglobulin heavy chain gene locus in B cells with increased risk of chromosomal translocation</td></tr><tr><td align="left" colspan="1" rowspan="1">High rate of mutation leading to B cell malignancies</td></tr><tr><td align="left" colspan="1" rowspan="1">Comorbidities</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Cardiovascular diseases</td><td align="left" colspan="1" rowspan="1">Modulation of adhesion molecules expression, with increased vascular adhesion of monocytes and endothelial dysfunction associated with atherosclerosis, coronary artery disease, myocarditis, and hypertrophic cardiomyopathy</td><td align="left" rowspan="2" colspan="1">[<xref ref-type="bibr" rid="CR123">123</xref>&#8211;<xref ref-type="bibr" rid="CR126">126</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Decrease of endothelium-dependent vasorelaxation and endothelial NOS production in coronary arteries</td></tr><tr><td align="left" colspan="1" rowspan="1">Nephropathy</td><td align="left" colspan="1" rowspan="1"><p>Increase of glomerular permeability by altering cytoskeleton organization and nephrin distribution in human podocytes</p><p>Renal expression of HIV genes, bFGF and VEGF-A</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">Osteoporosis</td><td align="left" colspan="1" rowspan="1">Reduced differentiation of bone marrow osteoblast precursor stem cells into osteoblastic cells</td><td align="left" rowspan="3" colspan="1">[<xref ref-type="bibr" rid="CR129">129</xref>&#8211;<xref ref-type="bibr" rid="CR131">131</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Upregulation of osteoclast bone resorption</td></tr><tr><td align="left" colspan="1" rowspan="1">Enhanced osteoclast differentiation</td></tr><tr><td align="left" rowspan="3" colspan="1">Enteropathy</td><td align="left" colspan="1" rowspan="1">Pro-oxidant and pro-apoptotic effects on colonic epithelial cells and consequent disruption of intestinal barrier integrity</td><td align="left" rowspan="3" colspan="1">[<xref ref-type="bibr" rid="CR132">132</xref>&#8211;<xref ref-type="bibr" rid="CR134">134</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Direct anti-proliferative effects on enterocytes, with intestinal mucosal atrophy</td></tr><tr><td align="left" colspan="1" rowspan="1">Increased excitability of the enteric nervous system</td></tr><tr><td align="left" colspan="1" rowspan="1">Pulmonary disease</td><td align="left" colspan="1" rowspan="1"><p>Suppression of CFTR with alteration of mucociliary clearance</p><p>Release of reactive oxygen species and activation of platelet-derived growth factor with development of pulmonary hypertension</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR135">135</xref>&#8211;<xref ref-type="bibr" rid="CR137">137</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">CNS neuropathy</td><td align="left" colspan="1" rowspan="1">Disruption of the blood-brain barrier and neuronal synapses</td><td align="left" rowspan="3" colspan="1">[<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR138">138</xref>&#8211;<xref ref-type="bibr" rid="CR141">141</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Increased expression of inducible NOS and NO release in astrocytes, microglia, and brain endothelial cells, with induction of oxidative stress, mitochondrial injury, and inflammation</td></tr><tr><td align="left" colspan="1" rowspan="1">Involvement in the development of HIV-1-associated neurocognitive disorders</td></tr><tr><td align="left" rowspan="4" colspan="1">Chronic immune activation and aging</td><td align="left" colspan="1" rowspan="1">Involvement in production of proinflammatory cytokines by dendritic cells and monocytes/macrophages</td><td align="left" rowspan="4" colspan="1">[<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR142">142</xref>&#8211;<xref ref-type="bibr" rid="CR144">144</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Activation of CD4<sup>+</sup> T cells, inducing the release of proinflammatory cytokines and the expression of transcription factors such as T-bet and Eomes</td></tr><tr><td align="left" colspan="1" rowspan="1">Alteration of functionality of CD8<sup>+</sup> T cells through the induction of T-bet, Eomes and Blimp-1 expression</td></tr><tr><td align="left" colspan="1" rowspan="1">Immune senescence by impairment of hTERT levels and telomerase activity in CD4<sup>+</sup> T&#160;cells</td></tr><tr><td align="left" colspan="1" rowspan="1">Opportunistic infections</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Viruses</td><td align="left" colspan="1" rowspan="1">Transactivation of heterologous viral promoters (JCV, CMV, HHV-6) directly or indirectly through TNF&#945;-induced NF-&#954;B signaling</td><td align="left" rowspan="3" colspan="1">[<xref ref-type="bibr" rid="CR145">145</xref>&#8211;<xref ref-type="bibr" rid="CR151">151</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Interaction with HSV-1 ICP0 to induce HIV-1 transcription and translation in HIV-1/HSV-1-coinfected cells</td></tr><tr><td align="left" colspan="1" rowspan="1">Increased viral replication and/or protein translation in HHV-8, HHV-6, or BKV-infected cells</td></tr><tr><td align="left" rowspan="3" colspan="1">Bacteria</td><td align="left" colspan="1" rowspan="1">Increased <italic toggle="yes">Mycobacterium avium</italic> replication efficiency in macrophages through integrin binding and increased production of TGF- &#946;1</td><td align="left" rowspan="7" colspan="1">[<xref ref-type="bibr" rid="CR152">152</xref>&#8211;<xref ref-type="bibr" rid="CR160">160</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Synergy with <italic toggle="yes">Mycobacterium smegmatis</italic>, BCG, <italic toggle="yes">Mycobacterium avium</italic>, and <italic toggle="yes">Mycobacterium tuberculosis</italic> to enhance HIV-LTR transcription</td></tr><tr><td align="left" colspan="1" rowspan="1">Enhanced bacterial proliferation through binding the promoters of genes regulating cell division (<italic toggle="yes">Escherichia coli</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic>)</td></tr><tr><td align="left" rowspan="4" colspan="1">Protozoa and fungi</td><td align="left" colspan="1" rowspan="1">Increased uptake and growth of <italic toggle="yes">Leishmania</italic> and other intracellular parasites by inducing TGF- &#946;1 or IL-10 expression</td></tr><tr><td align="left" colspan="1" rowspan="1">Reduced clearance of <italic toggle="yes">Cryptosporidium parvum</italic> by modulation of TLR translation in infected cholangiocytes</td></tr><tr><td align="left" colspan="1" rowspan="1">Binding to <italic toggle="yes">Candida albicans</italic> and accelerated germination and elongation</td></tr><tr><td align="left" colspan="1" rowspan="1">Increased phagocytosis of Tat-bound and serum-opsonised <italic toggle="yes">Candida albicans</italic> by monocytes</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: KS, Kaposi&#8217;s sarcoma; HHV, human herpes virus; bFGF, basic fibroblast growth factor; MMPs, matrix metalloproteinases; bcl-2, B-cell lymphoma 2; HPV, human papillomavirus; MAPK, mitogen-activated protein kinases; EBV, Epstein-Barr virus; JCV, John Cunningham virus; CMV, cytomegalovirus; TNF&#945;, tumor necrosis factor alpha; NF-&#954;B, nuclear factor kappa-light-chain-enhancer of activated B cells; HSV-1, herpes simplex virus 1; BCG, bacillus Calmette&#8211;Gu&#233;rin; TGF- &#946;1, transforming growth factor &#946;1; IL-10, interleukin 10; TLR, Toll-like receptor; VEGF-A, vascular endothelial growth factor A; NOS, nitric&#160;oxide synthase; NO, nitric&#160;oxide; HIV, human immunodeficiency virus; CFTR, cystic fibrosis transmembrane conductance regulator; T-bet, T-box&#160;expressed on T cells; Eomes, eomesodermin; hTERT, human telomerase reverse transcriptase</p></table-wrap-foot></table-wrap></p><p id="Par22">HIV-1 Tat has been implicated directly in the pathogenesis of AIDS-associated tumors, such as Kaposi&#8217;s sarcoma (KS), cervical cancer, and lymphoproliferative disorders, while only indirect evidence is available for those tumors whose risk is only modestly increased during HIV infection, such as lung and liver cancer (non-AIDS-defining cancers). In particular, Tat promotes the migration, invasion, and proliferation of KS cells and activated endothelial cells [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR101">101</xref>&#8211;<xref ref-type="bibr" rid="CR106">106</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). This is due to the ability of Tat to mimic and/or enhance the effects of extracellular matrix molecules, which regulate and enhance the effects of angiogenic growth factors on endothelial cell growth and locomotion through RGD-binding integrins that function as Tat receptors [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR101">101</xref>&#8211;<xref ref-type="bibr" rid="CR103">103</xref>]. Tat also induces angiogenesis and vascular permeability in synergy with angiogenic factors or inflammatory cytokines by activating matrix metalloproteinases (MMPs) [<xref ref-type="bibr" rid="CR92">92</xref>] and promotes the recruitment of HHV-8-infected circulating KS cells into tissues [<xref ref-type="bibr" rid="CR103">103</xref>], triggers HHV-8 reactivation from latency, and accelerates tumor progression induced by HHV-8-encoded oncoproteins [<xref ref-type="bibr" rid="CR107">107</xref>&#8211;<xref ref-type="bibr" rid="CR110">110</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par23">Moreover, among the various effects in the other AIDS-associated tumors, Tat can also interact with several oncogenes. For example, it upregulates HPV-E6 and -E7 oncoprotein activity in cervical cancer, thus increasing cell proliferation and survival and angiogenesis [<xref ref-type="bibr" rid="CR111">111</xref>&#8211;<xref ref-type="bibr" rid="CR116">116</xref>], and it promotes Myc repositioning near the immunoglobulin (Ig) heavy chain locus in normal B cells, thus increasing the risk of specific chromosomal translocations during lymphomagenesis [<xref ref-type="bibr" rid="CR117">117</xref>&#8211;<xref ref-type="bibr" rid="CR122">122</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par24">Individuals with HIV also have a disproportionate risk of various comorbidities to which the Tat protein appears to contribute. In particular, Tat plays an important role in HIV-related cardiac dysfunction by modulating the expression of adhesion molecules on the endothelium and facilitating the adhesion of monocytes [<xref ref-type="bibr" rid="CR123">123</xref>]. This leads to vascular inflammation and endothelial dysfunction, which is associated with the pathogenesis of cardiovascular complications affecting PLWH, including atherosclerosis, coronary artery disease, myocarditis, and hypertrophic cardiomyopathy [<xref ref-type="bibr" rid="CR124">124</xref>&#8211;<xref ref-type="bibr" rid="CR126">126</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). Tat may also contribute to functional alterations occurring in HIV-associated nephropathy by altering glomerular permeability and by inducing the redistribution and loss of nephrin in podocytes [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). By interfering with osteoblastic differentiation and enhancing osteoclast differentiation, Tat also contributes to increased osteopenia/osteoporosis affecting PLWH [<xref ref-type="bibr" rid="CR129">129</xref>&#8211;<xref ref-type="bibr" rid="CR131">131</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). Tat also plays a key role in HIV-1-associated intestinal disorders, as it alters the expression of many genes regulating survival and growth of enterocytes and the excitability of the enteric nervous system, contributing to the gut dysfunction that has been described in HIV patients [<xref ref-type="bibr" rid="CR132">132</xref>&#8211;<xref ref-type="bibr" rid="CR134">134</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). Moreover, Tat may be implicated in pulmonary complications in PLWH by altering mucociliary clearance and contributing to the development of pulmonary hypertension [<xref ref-type="bibr" rid="CR135">135</xref>&#8211;<xref ref-type="bibr" rid="CR137">137</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). Tat is also known to induce neurotoxicity by disrupting the blood-brain barrier and neuronal synapses, promoting oxidative stress in astrocytes, microglia, and brain endothelial cells, and activating inflammation, thus contributing to the development of HIV-1-associated neurocognitive disorders [<xref ref-type="bibr" rid="CR126">126</xref>, <xref ref-type="bibr" rid="CR128">128</xref>, <xref ref-type="bibr" rid="CR138">138</xref>&#8211;<xref ref-type="bibr" rid="CR141">141</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). Finally, Tat is involved in overstimulation of the immune system and production of the high level of inflammatory responses seen in HIV-infected patients, contributing to the exacerbation of several immune dysfunctions observed during disease progression, such as chronic immune activation and premature aging [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR142">142</xref>&#8211;<xref ref-type="bibr" rid="CR144">144</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par25">HIV-1 Tat has also been shown to interact with various opportunistic pathogens during AIDS progression, increasing the incidence and severity of infections. In this context, Tat can increase the transcription of the genomes of other viruses, such as John Cunningham virus (JCV) [<xref ref-type="bibr" rid="CR145">145</xref>], cytomegalovirus (CMV) [<xref ref-type="bibr" rid="CR145">145</xref>], and HHV-6 [<xref ref-type="bibr" rid="CR146">146</xref>], either directly, by binding heterologous viral promoters, or indirectly, by activating the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-&#954;B) signaling pathway through its binding to the tumor necrosis factor alpha (TNF-&#945;) promoter (Table <xref rid="Tab1" ref-type="table">1</xref>). Tat also modulates the transcription and translation of herpes simplex viruses, and of HHV-6 and HHV-8 [<xref ref-type="bibr" rid="CR146">146</xref>&#8211;<xref ref-type="bibr" rid="CR151">151</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>), which are considered cofactors for the development of several tumors, including nodular sclerosis Hodgkin lymphoma, gastrointestinal cancer, glial tumors, and/or KS.</p><p id="Par26">Moreover, via its RGD motif, Tat can bind integrins present on the surface of pathogens such as mycobacteria and fungi [<xref ref-type="bibr" rid="CR152">152</xref>, <xref ref-type="bibr" rid="CR153">153</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). This binding increases mycobacterial replication efficiency and accelerates the germination and elongation of <italic toggle="yes">Candida albicans</italic> to form pseudohyphae, contributing to the increased severity of these opportunistic infections in HIV-infected patients [<xref ref-type="bibr" rid="CR154">154</xref>&#8211;<xref ref-type="bibr" rid="CR156">156</xref>]. In addition, HIV-1 Tat can cooperate with bacteria to synergistically enhance transcription from the HIV LTR and can regulate some bacterial gene expression and proliferation [<xref ref-type="bibr" rid="CR157">157</xref>, <xref ref-type="bibr" rid="CR158">158</xref>] (Table <xref rid="Tab1" ref-type="table">1</xref>). HIV-1 Tat has also been shown to interact with protozoa of the family Trypanosomatidae [<xref ref-type="bibr" rid="CR159">159</xref>, <xref ref-type="bibr" rid="CR160">160</xref>]. It was reported to induce the uptake of <italic toggle="yes">Leishmania</italic> parasites and to increase their intracellular growth (Table <xref rid="Tab1" ref-type="table">1</xref>). Thus, in HIV coinfections, Tat enhances infection and replication of both pathogens and HIV-1, further worsening the infectious burden in the host.</p><p id="Par27">Taken together, all of these findings provide a strong rationale for targeting Tat in intervention strategies aimed at improving the clinical management and the quality of life of PLWH, even in the cART era.</p></sec></sec><sec id="Sec10"><title>The Tat-based concept for HIV vaccine development</title><sec id="Sec11"><title>Regulation of immune responses by HIV Tat</title><p id="Par28">The biologically active Tat protein displays immunomodulatory features that make it an attractive antigen, alone or combined with other HIV proteins, for the design of new HIV vaccines [<xref ref-type="bibr" rid="CR161">161</xref>&#8211;<xref ref-type="bibr" rid="CR165">165</xref>]. In particular, native Tat protein is very efficiently taken up by monocyte-derived dendritic cells and, upon cellular entry, promotes DC maturation and activation, leading to a more efficient presentation of both allogeneic and exogenous antigens and resulting in an increased antigen-specific T cell response [<xref ref-type="bibr" rid="CR52">52</xref>]. By modifying the catalytic subunit composition of the immunoproteasome, the Tat protein broadens epitope-specific CTL and Th-1 immune responses to heterologous antigens [<xref ref-type="bibr" rid="CR161">161</xref>&#8211;<xref ref-type="bibr" rid="CR166">166</xref>]. Moreover, through its basic domain, Tat increases the surface expression of peptides complexed with MHC class I molecules [<xref ref-type="bibr" rid="CR167">167</xref>], whereas dimerization promoted by the cysteine-rich region confers on Tat the capability to trigger strong immune response against itself as well as other antigens [<xref ref-type="bibr" rid="CR168">168</xref>].</p><p id="Par29">Taken together, these findings clearly demonstrate that Tat is not only an antigen but also a novel and potent immunoregulatory protein capable of promoting Th-1 responses and broadening the spectrum of epitopes recognized by T cells. This property may be important for the design of adjuvant-free Tat-based vaccines, or for using Tat as an immunoregulator to improve the efficacy of other vaccines. It is noteworthy that co-immunization with Env and Gag proteins together with Tat induces T-cell responses to all of these antigens, ruling out potential interference and providing evidence that a vaccine formulation containing Tat and other relevant HIV target proteins is feasible, and it may have the advantage of controlling virus replication at both the early and late stages of the infection [<xref ref-type="bibr" rid="CR165">165</xref>]. The inherent ability of Tat to broaden the T cell repertoire may indeed be particularly relevant in vaccination strategies against other viral infections or tumors. In fact, it is widely held that increasing the size and broadening the diversity of T cell responses to a given antigen would increase the efficacy of a vaccine and reduce epitope mutation and CTL escape [<xref ref-type="bibr" rid="CR165">165</xref>, <xref ref-type="bibr" rid="CR166">166</xref>]. In this regard, vaccination with a live attenuated herpes simplex virus (HSV) vector expressing Tat increased memory CD8<sup>+</sup> T cell responses against epitopes present in subjects without recurrences, who were therefore called &#8220;asymptomatic&#8221;, and it was considered protective, inducing anti-HSV IgG2a (an indicator of a Th1-driven B cell response) and protecting mice from death after a lethal challenge with wild-type HSV [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR169">169</xref>&#8211;<xref ref-type="bibr" rid="CR171">171</xref>]. In particular, Tat increases <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> IFN-&#947;, granzyme B, and interleukin-2 (IL-2) release [<xref ref-type="bibr" rid="CR142">142</xref>, <xref ref-type="bibr" rid="CR144">144</xref>], and in mice, injection with Tat increases the frequency of HSV1-specific effector memory CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR142">142</xref>], which are associated with asymptomatic HSV infection in humans [<xref ref-type="bibr" rid="CR172">172</xref>]. Finally, Tat upregulates expression of T-box in T cells (T-bet), Eomes, B lymphocyte-induced maturation protein 1 (Blimp-1), and Bcl-2 in activated CD8<sup>+</sup> T cells [<xref ref-type="bibr" rid="CR144">144</xref>], factors that are upregulated in HSV1-specific CD8<sup>+</sup> T cells of asymptomatic but not symptomatic individuals [<xref ref-type="bibr" rid="CR173">173</xref>]. Thus, inclusion of the tat gene in attenuated or replication-defective HSV1-based vectors is an innovative strategy for development of effective preventive and therapeutic HSV vaccines. Furthermore, administration of Tat to mice acutely infected with <italic toggle="yes">Mycobacterium tuberculosis</italic> (Mtb) significantly reduced leucocyte infiltration and tissue damage in the lung, suggesting a modulatory role for Tat, also in the early response to Mtb, affecting tuberculosis pathogenesis [<xref ref-type="bibr" rid="CR174">174</xref>].</p></sec><sec id="Sec12"><title>Role of the immune response to Tat</title><sec id="Sec13"><title>Epidemiological evidence</title><p id="Par30">Epidemiological studies have shown that asymptomatic patients and non-progressors have a higher prevalence of anti-Tat Abs than progressors [<xref ref-type="bibr" rid="CR175">175</xref>], as shown by a slower and milder evolution of the disease and a better responsiveness to antiretroviral therapy. In particular, the presence of anti-Tat Abs correlates with a significant containment of CD4<sup>+</sup> T cell loss and plasma viral load (VL) increases [<xref ref-type="bibr" rid="CR175">175</xref>&#8211;<xref ref-type="bibr" rid="CR183">183</xref>]. Regarding cell-mediated immunity, CTLs to Tat are frequently detected in asymptomatic HIV-1-infected individuals and have been shown to inversely correlate with progression to AIDS [<xref ref-type="bibr" rid="CR184">184</xref>, <xref ref-type="bibr" rid="CR185">185</xref>]. Because HIV-infected cells express Tat very early after infection, vaccine-induced anti-Tat CTLs may eliminate infected cells and block HIV infection at an early stage. Furthermore, the detection of anti-Tat CTL escape mutants early after infection in humans highlights the selective pressure that the immune system exerts on Tat and the importance of anti-Tat CTLs early after infection [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR187">187</xref>]. Thus, the control of HIV replication by CTLs targeted to early proteins, and in particular to Tat, is relevant for the containment of the infection and progression to disease. Indeed, we have very recently reported [<xref ref-type="bibr" rid="CR188">188</xref>] that, in individuals on long-term ART, anti-Tat immunity was associated with higher nadir CD4<sup>+</sup> T-cell counts, control of low-level viremia, and long-lasting CD4<sup>+</sup> T cell recovery, but not with decreased immune activation. In particular, individuals with both humoral responses and a high frequency of cell-mediated responses experienced a progressive increase in CD4<sup>+</sup> T cells and the CD4<sup>+</sup>/CD8<sup>+</sup> T-cell ratio. These changes were not observed in individuals lacking these responses. Furthermore, the cell-mediated response to Tat, alone or associated with the anti-Tat Ab response, was also found to be predictive of a significant increase in NK or B cells, respectively. Notably, the anti-Tat antibody level was associated with control of very-low-level viremia, suggesting a block of HIV reactivation from virus reservoirs by Abs targeting extracellular Tat [<xref ref-type="bibr" rid="CR188">188</xref>].</p><p id="Par31">Altogether, these studies indicate that both the cellular and humoral Tat-specific immune response contribute to the control of infection and/or disease progression.</p></sec><sec id="Sec14"><title>Preclinical studies with a Tat-based vaccine</title><p id="Par32">Based on the above epidemiological evidence and its key role in the HIV life cycle and disease pathogenesis, the Tat protein was chosen as a vaccine candidate for preclinical and clinical development for the prevention and treatment of HIV-1 infection. In preclinical studies in nonhuman primates, the Tat protein or tat DNA were found to be safe and to elicit a broad and specific immune response, which protected macaques against challenges with the X4-tropic SHIV89.6P [<xref ref-type="bibr" rid="CR189">189</xref>&#8211;<xref ref-type="bibr" rid="CR194">194</xref>]. In particular, Tat-specific Ab levels and CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses were high and stable only in the animals that controlled primary infection at its early stages. Of interest, vaccinated and protected macaques did not experience virus rebound upon administration of tetanus toxoid, a stimulus known to activate the immune system and to trigger HIV replication [<xref ref-type="bibr" rid="CR192">192</xref>]. In addition, vaccinees, but not control animals, were able to contain a second, fivefold higher, intravenous challenge with the same virus upon initial overt infection [<xref ref-type="bibr" rid="CR193">193</xref>]. Overall, these results indicate that vaccination with Tat had induced long-term memory Tat-specific immune responses, allowing long-term containment of virus replication and spread in blood and tissues.</p><p id="Par33">Co-immunization with Tat and other HIV antigens, particularly with Env, underscores the contribution of anti-Tat immunity to vaccine efficacy. In particular, no infection or a statistically significant reduction of viral load and proviral DNA was observed in cynomolgus macaques that had been co-immunized with HIV-1 Tat and Env-&#916;V2 (an oligomeric gp140 protein deleted of&#160;the V2 region) proteins in a complex and challenged intrarectally with a high dose (70 MID<sub>50</sub>) of the R5-tropic SHIV<sub>SF162P4cy</sub> [<xref ref-type="bibr" rid="CR35">35</xref>]. Rhesus macaques were immunized mucosally with replicating adenovirus vectors carrying the HIV-1 clade B tat and env transgenes and then boosted at the systemic level with the Tat and Env proteins. All macaques became infected following intravenous challenge with a high dose of homologous SHIV-89.6P. However, macaques vaccinated with Tat/Env displayed a 4-log lower chronic viremia and experienced a mild CD4<sup>+</sup> T cell loss as compared to control animals [<xref ref-type="bibr" rid="CR195">195</xref>]. Furthermore, sterilizing immunity or control of infection was observed in rhesus macaques immunized with a multicomponent vaccine (multimeric HIV-1 clade C gp160, HIV-1 clade B Tat, and SIV Gag-Pol particles) delivered either systemically or mucosally and then challenged with the heterologous HIV-C env SHIV-1157ip [<xref ref-type="bibr" rid="CR196">196</xref>]. The search for humoral correlates of protection identified anti-Tat Abs against the N-terminus of Tat as a relevant one, a finding corroborated by binding and functional assays [<xref ref-type="bibr" rid="CR197">197</xref>]. Thus, in monkey models of efficacy, both humoral and cellular anti-Tat immunity plays a role in preventing infection and disease progression. Furthermore, Tat/Env co-immunization studies also indicate a role of Tat in modulating the immunogenicity of Env towards potentially protective responses.</p></sec><sec id="Sec15"><title>Clinical development: preventative and therapeutic phase I trials</title><p id="Par34">Based on these results, preventative and therapeutic, double blind, placebo-controlled phase I trials with the biologically active Tat (ISS P-001, ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00529698">NCT00529698</ext-link>; ISS T-001, ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00505401">NCT00505401</ext-link>) were conducted in Italy, meeting both primary (safety) and secondary (immunogenicity) endpoints [<xref ref-type="bibr" rid="CR198">198</xref>&#8211;<xref ref-type="bibr" rid="CR200">200</xref>]. The Tat vaccine was safe and, in the HIV-infected volunteers, did not induce virus replication, as indicated by preservation the of CD4<sup>+</sup> T cell counts and by the absence of significant plasma viremia rebounds. The long-term follow-up (ISS OBS P-001, ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01024764">NCT01024764</ext-link>) showed the persistence of anti-Tat NAbs up to five years after the first immunization [<xref ref-type="bibr" rid="CR199">199</xref>, <xref ref-type="bibr" rid="CR200">200</xref>].</p><p id="Par35">A phase I preventive trial was also conducted with the combination of Tat and V2-loop-deleted Env (&#8710;V2-Env) in Italy (ISS P-002, ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01441193">NCT01441193</ext-link>). This was a multicentric, open-label, phase I trial conducted in healthy volunteers to evaluate the safety and the immunogenicity of the vaccine based on the association of HIV-1 Tat and &#8710;V2-Env proteins, as compared to vaccination with single proteins. Tat and &#8710;V2-Env proteins, either in association or as single components, were administered by a prime-boost regimen consisting of three intradermal priming doses followed by two intramuscular boosting injections. The Tat/&#8710;V2-Env vaccination was safe and immunogenic, as indicated by the development of Ab responses to the vaccine antigen(s) in all participants [Ensoli, unpublished data]. Importantly, while the highest anti-Tat Ab response was detected in the subjects vaccinated with Tat alone, the highest anti-Env Ab responses were recorded in the volunteers co-immunized with Tat/&#8710;V2-Env, which is consistent with previous studies showing better priming provided by Tat-mediated entry of Env in dendritic cells [<xref ref-type="bibr" rid="CR165">165</xref>].</p></sec><sec id="Sec16"><title>Clinical development: therapeutic phase II trials</title><p id="Par36">Moving forward, the therapeutic vaccination was prioritized over the preventive one as a shorter and more cost-effective route to proof of efficacy [<xref ref-type="bibr" rid="CR201">201</xref>]. Therapeutic phase II trials for cART intensification were conducted in Italy and South Africa in patients on successful cART. The Italian phase II study (ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00751595">NCT00751595</ext-link>) was an exploratory phase II open-label therapeutic trial, randomized on the different regimens utilized [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. It enrolled 168 HIV-infected (B clade) anti-Tat Ab-negative adults on long-term (mean &gt;6 years) cART who were virologically suppressed, with CD4<sup>+</sup> T cell counts &#8805;200 cells/mmc, and were vaccinated with 7.5 or 30 &#956;g of the Tat protein (clade B) without adjuvant, administered intradermally 3 or 5 times, one month apart. Both primary (immunogenicity) and secondary (safety) endpoints were met. No increase in virological biomarkers was observed. The results also showed a reduction in immune activation and durable increases in CD4<sup>+</sup> T cells, B cells, NK cells, and CD4<sup>+</sup> and CD8<sup>+</sup> central memory T cell subsets, with a reduction in effector memory cells, indicating a shift of the immune response towards homeostasis [<xref ref-type="bibr" rid="CR77">77</xref>]. None of these changes were observed in anti-Tat-Ab-negative subjects on effective cART enrolled in a parallel observational study at the same clinical centers (ISS OBS T-002) (ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01024556">NCT01024556</ext-link>) [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>]. Of note, Tat immunization induced a reduction of HIV-1 DNA load in blood, especially in volunteers receiving 30 &#956;g of Tat, given three times, that continued throughout the 8-year follow-up (ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02118168">NCT02118168</ext-link>) [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR202">202</xref>]. Tat-specific cellular responses also contributed to HIV proviral DNA reduction. Furthermore, the induction, upon vaccination, of CD38<sup>+</sup>/HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells and natural killer (NK) cells endowed with killer activity against virus-infected cells may have also contributed to the reduction of the virus reservoir. cART intensification by the Tat vaccine was durable, as the increase in CD4<sup>+</sup> T cells persisted during the 8-year follow-up and was accompanied by a progressive, slow decrease in HIV proviral DNA in the peripheral blood, which became undetectable in 34% of all vaccinees and in 48% of volunteers in the group receiving 30 &#956;g of Tat three times [<xref ref-type="bibr" rid="CR202">202</xref>]. These results indicate that the induction of anti-Tat immune responses intensifies cART efficacy and attacks the cART-resistant virus reservoir. A confirmatory randomized, double-blind, placebo-controlled (randomization ratio, 1:1), safety and immunogenicity phase II therapeutic trial (ISS T-003, ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01513135">NCT01513135</ext-link>) was then conducted in South Africa in 200 HIV-infected (C clade) anti-Tat Ab-negative adults who were virologically suppressed, with CD4<sup>+</sup> T cell counts &#8805;200 cells/mmc [<xref ref-type="bibr" rid="CR203">203</xref>]. The clade-B Tat vaccine (30 &#956;g) was administered intradermally three times at monthly intervals. The vaccine was safe and induced durable and high titers of anti-Tat Abs that were capable of cross-recognizing the Tat protein from different HIV clades and cross-neutralizing both clade B and C HIV viruses. Cross-recognition and cross-neutralization correlated with an increase in CD4<sup>+</sup> T cell counts, a key target for cART intensification [<xref ref-type="bibr" rid="CR203">203</xref>]. Of note, vaccination contained the VL rebound and maintained CD4<sup>+</sup> T cell counts above the baseline levels in subjects who were noncompliant with therapy as compared to (noncompliant) placebo, suggesting that Tat vaccine intensification of cART may counterbalance incomplete adherence to treatment [<xref ref-type="bibr" rid="CR203">203</xref>]. An extended follow-up study of this trial (ISS T-003 EF-UP) is underway. Overall, the Tat vaccine study shows for the first time that cART can be intensified by therapeutic immunization and that the proviral DNA load can be progressively lowered.</p></sec></sec></sec><sec id="Sec17"><title>Conclusions</title><p id="Par37">So far, HIV vaccine design based on structural proteins has not been successful, nor have empirical vaccines, reinforcing the concept that a pathogenetic approach must be undertaken to identify key virulence factors to target with a vaccine. In particular, a &#8220;pathogenesis-driven&#8221; approach should be aimed at targeting key viral products responsible of virus transmission and activation and maintenance of virus reservoirs. For this, evidence provided by the natural history of infection and lessons from earlier trials are key.</p><p id="Par38">Tat vaccination represents an example of a &#8220;pathogenic-driven&#8221; intervention that is potentially effective for both preventative and therapeutic strategies, since it is aimed at blocking virus transmission and spread. The rationale is based on the evidence that HIV-1 Tat, which is necessary for HIV gene expression, replication, and cell-to cell transmission, appears also to be critical in the initial steps of virus acquisition. In fact, it has been shown that Tat, which is present on virus particles, binds to Env spikes, promoting HIV infection of dendritic cells and spreading to T lymphocytes, even in the presence of anti-Env NAbs, and that anti-Tat Abs are necessary to restore neutralization and prevent HIV dissemination, as demonstrated by virus containment at the site of inoculation in macaques vaccinated with Tat and Env-&#916;V2 proteins and challenged intrarectally with the SHIV<sub>SF162P4cy</sub>, but not in control animals [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par39">In a therapeutic setting, cART intensification by a Tat vaccine has proven effective at promoting immune system restoration by improving CD4<sup>+</sup> T cell recovery and immune system functions while reducing virus reservoirs and immune activation/dysregulation [<xref ref-type="bibr" rid="CR77">77</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR202">202</xref>]. These combined effects may reduce the negative effects of non-adherence to therapy on virus transmission, and hence global community VL, new infections, and drug resistance. Thus, an intervention that restores immune responses may allow periodic drug-free time.</p><p id="Par40">The different therapeutic uses of Tat vaccination in HIV infection must be confirmed in dedicated trials to determine whether administration of Tat in patients receiving long-term (late) cART can provide prolonged post-treatment control (extended drug-free periods with low or undetectable VL) in an analytic treatment interruption (ATI) trial, opening new perspectives for functional cure and eradication strategies. In this regard, the durability of the increase in CD4<sup>+</sup> T cell count and the progressive decrease in HIV proviral DNA to undetectable levels observed in vaccinees over the 8-year follow-up [<xref ref-type="bibr" rid="CR202">202</xref>] are promising, as a reduced proviral HIV-1 DNA load at study entry has been reported to be independently associated with a delayed and milder HIV-1 RNA rebound after ATI [<xref ref-type="bibr" rid="CR204">204</xref>] and post-treatment control [<xref ref-type="bibr" rid="CR205">205</xref>].</p><p id="Par41">Moreover, in volunteers who were vaccinated with Tat toxoid and developed a high titer of Abs that neutralized Tat bioactivity, a prolonged off-therapy time was recorded in the 2 years of follow-up [<xref ref-type="bibr" rid="CR206">206</xref>]. Similarly, a delayed and weaker HIV RNA rebound was observed upon ATI in the volunteers immunized with Tat Oyi, who mounted strong immune responses against Tat [<xref ref-type="bibr" rid="CR207">207</xref>]. Of note, the 33-&#956;g dose was the most immunogenic and efficacious of the three doses tested (11, 33, and 99 &#181;g) [<xref ref-type="bibr" rid="CR207">207</xref>], which is in substantial agreement with our data from the ISS&#160;T-002 trial, in which the 30-&#956;g dose of recombinant Tat protein gave the best results [<xref ref-type="bibr" rid="CR78">78</xref>].</p><p id="Par42">The Tat vaccine should also be evaluated in poor immunological responders to determine whether it ameliorates the response to cART at the beginning of therapy, with the aim of reducing the time to a virological and immunological response. It is also important to evaluate the Tat vaccine in HIV-infected cART-treated adolescents and children, as they face the longest time on antiretroviral treatment and therefore are the ones most needing approaches ensuring virus control despite poor adherence, adoption of therapy simplification regimens, or prolonged time off-therapy. Furthermore, Tat could be used as a co-treatment to improve the efficacy of pre-exposure prophylaxis. It will be very important to evaluate the effects of the Tat vaccine in these contexts on HIV DNA in lymphoid tissues and other compartments, as cART does not attack the latent HIV reservoir, to determine the impact of vaccination on solid-tissue HIV reservoirs and residual disease. If proven effective in phase III efficacy trials, cART intensification by the Tat vaccine will allow the public health system to better target resources towards more-advanced HIV care strategies. In fact, cART intensification by the Tat vaccine is expected to reduce the rate of treatment failure and the prevalence of AIDS and non-AIDS comorbidities and allow periodic drug-free time, particularly in infants, children, and adolescents facing lifelong cART and its severe side-effects, which can lead to low therapy adherence. Moreover, further depletion of the reservoirs of cART-resistant latent HIV resulting from Tat vaccination promises to blunt HIV rebound upon low adherence, which is one of the main causes of the development of drug resistance and virus transmission. Notably, vaccination with Tat in &#8220;very early&#8221; treatment of acute infection could stall the expansion of HIV reservoirs, opening new perspectives for a functional cure for HIV infection.</p><p id="Par43">The generation of anti-Tat monoclonal Abs (mAbs) for immunotherapy should also be considered, as major advancements have been made in the generation and use of mAbs for immunotherapy [<xref ref-type="bibr" rid="CR208">208</xref>]. In the few studies that have been conducted so far, mAbs generated in murine models and in humans upon vaccination with the Tat protein and directed against the amino terminus of Tat were effective at blocking Tat-induced transactivation and viral replication [<xref ref-type="bibr" rid="CR209">209</xref>, <xref ref-type="bibr" rid="CR210">210</xref>], even across different Tat clades [<xref ref-type="bibr" rid="CR211">211</xref>]. Thus, studies thoroughly addressing the protective effects of anti-Tat mAbs, alone or in association with other therapeutic interventions (cART, broadly neutralizing Abs, latency-reversing agents, etc.) in preclinical models and then in humans, are warranted.</p><p id="Par44">Finally, the inherent Th-1- and CTL-promoting properties of Tat indicate the Tat may represent a new weapon that can be used as a vaccine against HIV/AIDS and as a potent Th-1 regulatory protein for increasing the efficacy of vaccines against other intracellular pathogens, such as HSV and Mtb.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank A. Arancio, M. Campagna, V. Francavilla, G. Paniccia, and M.R. Pavone Cossut (National HIV/AIDS Research Center) for laboratory support; F. Cammisa (National HIV/AIDS Research Center) for support to study management and editorial assistance; S. De Menna, F. Fedeli, and S. Tobelli (National HIV/AIDS Research Center) for administrative support; P. Arciero (National HIV/AIDS Research Center) for technical support; and G.B. Cozzone (VAXXIT, Rome, Italy) for helpful discussion</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization, B.E., P.M., S.B., S.M., M.T.M, A.B., and A.C.; methodology, A.C., P.M., S.B., A.T., C.S. and B.E.; data curation, A.T. and O.P.; writing&#8212;original draft preparation, S.M., M.T.M, A.B., writing&#8211;review and editing, A.C., P.M., S.B., C.S., S.M., M.T.M, A.B., and B.E.; supervision, A.C., P.M., and B.E.; funding acquisition, A.C., P.M. and B.E.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by the Italian Ministry of Health, Special Project on the Development of a Vaccine against HIV Based on the Tat protein, the Italian Ministry of Health, grant number F-2011-02348970 and RF-2016-02364744.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par45">The authors declare no conflict of interest. The funders had no role in the conceptualization of the study, in the collection, analysis or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>LP</given-names></name><name name-style="western"><surname>Fiore-Gartland</surname><given-names>A</given-names></name><name name-style="western"><surname>Carpp</surname><given-names>LN</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>KW</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N</given-names></name><name name-style="western"><surname>Fleurs</surname><given-names>L</given-names></name><etal/></person-group><article-title>Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans</article-title><source>PLoS One</source><year>2020</year><volume>15</volume><fpage>e0226803</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0226803</pub-id><pub-id pub-id-type="pmid">31999736</pub-id><pub-id pub-id-type="pmcid">PMC6992005</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Archin</surname><given-names>NM</given-names></name><name name-style="western"><surname>Marsh Sung</surname><given-names>J</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>C</given-names></name><name name-style="western"><surname>Soriano-Sarabia</surname><given-names>N</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>DM</given-names></name></person-group><article-title>Eradicating HIV-1 infection: seeking to clear a persistent pathogen</article-title><source>Nat Rev Microbiol</source><year>2014</year><volume>12</volume><fpage>750</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3352</pub-id><pub-id pub-id-type="pmid">25402363</pub-id><pub-id pub-id-type="pmcid">PMC4383747</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassen</surname><given-names>K</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Siliciano</surname><given-names>J</given-names></name><name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>The multifactorial nature of HIV-1 latency</article-title><source>Trends Mol Med</source><year>2004</year><volume>10</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2004.09.006</pub-id><pub-id pub-id-type="pmid">15519278</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esparza</surname><given-names>J</given-names></name></person-group><article-title>A brief history of the global effort to develop a preventive HIV vaccine</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3502</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.018</pub-id><pub-id pub-id-type="pmid">23707164</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>SA</given-names></name></person-group><article-title>Correlates of protection induced by vaccination</article-title><source>Clin Vaccine Immunol</source><year>2010</year><volume>17</volume><fpage>1055</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1128/CVI.00131-10</pub-id><pub-id pub-id-type="pmid">20463105</pub-id><pub-id pub-id-type="pmcid">PMC2897268</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ara&#250;jo</surname><given-names>LA</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>SE</given-names></name></person-group><article-title>HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition</article-title><source>Viruses</source><year>2013</year><volume>5</volume><fpage>595</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.3390/v5020595</pub-id><pub-id pub-id-type="pmid">23389465</pub-id><pub-id pub-id-type="pmcid">PMC3640516</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yates</surname><given-names>NL</given-names></name><name name-style="western"><surname>deCamp</surname><given-names>AC</given-names></name><name name-style="western"><surname>Korber</surname><given-names>BT</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Irene</surname><given-names>C</given-names></name><name name-style="western"><surname>Pinter</surname><given-names>A</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>J</given-names></name><name name-style="western"><surname>Harris</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>S</given-names></name><name name-style="western"><surname>Hraber</surname><given-names>P</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Nitayapan</surname><given-names>S</given-names></name><name name-style="western"><surname>Berman</surname><given-names>PW</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><name name-style="western"><surname>Pantaleo</surname><given-names>G</given-names></name><name name-style="western"><surname>Zolla-Pazner</surname><given-names>S</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name><name name-style="western"><surname>Alam</surname><given-names>SM</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name></person-group><article-title>HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees</article-title><source>J Virol</source><year>2018</year><volume>92</volume><issue>8</issue><fpage>e01843-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.01843-17</pub-id><pub-id pub-id-type="pmid">29386288</pub-id><pub-id pub-id-type="pmcid">PMC5874409</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMichael</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Callan</surname><given-names>M</given-names></name><name name-style="western"><surname>Appay</surname><given-names>V</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T</given-names></name><name name-style="western"><surname>Ogg</surname><given-names>G</given-names></name><name name-style="western"><surname>Rowland-Jones</surname><given-names>S</given-names></name></person-group><article-title>The dynamics of the cellular immune response to HIV infection: implications for vaccination</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>2000</year><volume>355</volume><fpage>1007</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1098/rstb.2000.0637</pub-id><pub-id pub-id-type="pmid">11186301</pub-id><pub-id pub-id-type="pmcid">PMC1692807</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMichael</surname><given-names>A</given-names></name><name name-style="western"><surname>Hanke</surname><given-names>T</given-names></name></person-group><article-title>The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?</article-title><source>Nat Rev Immunol</source><year>2002</year><volume>2</volume><fpage>283</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/nri779</pub-id><pub-id pub-id-type="pmid">12001999</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMichael</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Borrow</surname><given-names>P</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name><name name-style="western"><surname>Goonetilleke</surname><given-names>N</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name></person-group><article-title>The immune response during acute HIV-1 infection: clues for vaccine development</article-title><source>Nat Rev Immunol</source><year>2010</year><volume>10</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/nri2674</pub-id><pub-id pub-id-type="pmid">20010788</pub-id><pub-id pub-id-type="pmcid">PMC3119211</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mudd</surname><given-names>PA</given-names></name><name name-style="western"><surname>Martins</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ericsen</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Tully</surname><given-names>DC</given-names></name><name name-style="western"><surname>Power</surname><given-names>KA</given-names></name><name name-style="western"><surname>Bean</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Vaccine-induced CD8+ T cells control AIDS virus replication</article-title><source>Nature</source><year>2012</year><volume>491</volume><fpage>129</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nature11443</pub-id><pub-id pub-id-type="pmid">23023123</pub-id><pub-id pub-id-type="pmcid">PMC3883109</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koup</surname><given-names>RA</given-names></name><name name-style="western"><surname>Roederer</surname><given-names>M</given-names></name><name name-style="western"><surname>Lamoreaux</surname><given-names>L</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>J</given-names></name><name name-style="western"><surname>Novik</surname><given-names>L</given-names></name><name name-style="western"><surname>Nason</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and Tcell responses</article-title><source>PLoS One</source><year>2010</year><volume>5</volume><fpage>e9015</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0009015</pub-id><pub-id pub-id-type="pmid">20126394</pub-id><pub-id pub-id-type="pmcid">PMC2814848</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name></person-group><article-title>Novel adenovirus vector-based vaccines for HIV-1</article-title><source>Curr Opin HIV AIDS</source><year>2010</year><volume>5</volume><fpage>386</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1097/COH.0b013e32833cfe4c</pub-id><pub-id pub-id-type="pmid">20978378</pub-id><pub-id pub-id-type="pmcid">PMC2967414</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilks</surname><given-names>AB</given-names></name><name name-style="western"><surname>Christian</surname><given-names>EC</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Sircar</surname><given-names>P</given-names></name><name name-style="western"><surname>Carville</surname><given-names>A</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>CE</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M</given-names></name><name name-style="western"><surname>Pantaleo</surname><given-names>G</given-names></name><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name><name name-style="western"><surname>Letvin</surname><given-names>NL</given-names></name><name name-style="western"><surname>Permar</surname><given-names>SR</given-names></name></person-group><article-title>Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys</article-title><source>J Immunol</source><year>2010</year><volume>185</volume><fpage>7097</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1002751</pub-id><pub-id pub-id-type="pmid">21041730</pub-id><pub-id pub-id-type="pmcid">PMC3017679</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>AIDS research. Promising AIDS vaccine&#8217;s failure leaves field reeling</article-title><source>Science</source><year>2007</year><volume>318</volume><fpage>28</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1126/science.318.5847.28</pub-id><pub-id pub-id-type="pmid">17916696</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duerr</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>S</given-names></name><name name-style="western"><surname>Coombs</surname><given-names>RW</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>J</given-names></name><name name-style="western"><surname>del Rio</surname><given-names>C</given-names></name><etal/></person-group><article-title>Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)</article-title><source>J Infect Dis</source><year>2012</year><volume>206</volume><fpage>258</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis342</pub-id><pub-id pub-id-type="pmid">22561365</pub-id><pub-id pub-id-type="pmcid">PMC3490694</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchbinder</surname><given-names>SP</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>DV</given-names></name><name name-style="western"><surname>Duerr</surname><given-names>A</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>DW</given-names></name><name name-style="western"><surname>Mogg</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>1881</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)61591-3</pub-id><pub-id pub-id-type="pmid">19012954</pub-id><pub-id pub-id-type="pmcid">PMC2721012</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammer</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sobieszczyk</surname><given-names>ME</given-names></name><name name-style="western"><surname>Janes</surname><given-names>H</given-names></name><name name-style="western"><surname>Karuna</surname><given-names>ST</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Grove</surname><given-names>D</given-names></name><name name-style="western"><surname>Koblin</surname><given-names>BA</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>SP</given-names></name><name name-style="western"><surname>Keefer</surname><given-names>MC</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name><name name-style="western"><surname>Frahm</surname><given-names>N</given-names></name><name name-style="western"><surname>Hural</surname><given-names>J</given-names></name><name name-style="western"><surname>Anude</surname><given-names>C</given-names></name><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name><name name-style="western"><surname>Enama</surname><given-names>ME</given-names></name><name name-style="western"><surname>Adams</surname><given-names>E</given-names></name><name name-style="western"><surname>DeJesus</surname><given-names>E</given-names></name><name name-style="western"><surname>Novak</surname><given-names>RM</given-names></name><name name-style="western"><surname>Frank</surname><given-names>I</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>C</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S</given-names></name><name name-style="western"><surname>Fu</surname><given-names>R</given-names></name><name name-style="western"><surname>Koup</surname><given-names>RA</given-names></name><name name-style="western"><surname>Mascola</surname><given-names>JR</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Kublin</surname><given-names>J</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></name></person-group><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>2083</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1310566</pub-id><pub-id pub-id-type="pmid">24099601</pub-id><pub-id pub-id-type="pmcid">PMC4030634</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>GE</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Metch</surname><given-names>B</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>PB</given-names></name><name name-style="western"><surname>Bekker</surname><given-names>LG</given-names></name><name name-style="western"><surname>Churchyard</surname><given-names>G</given-names></name><name name-style="western"><surname>Nchabeleng</surname><given-names>M</given-names></name><name name-style="western"><surname>Mlisana</surname><given-names>K</given-names></name><name name-style="western"><surname>Laher</surname><given-names>F</given-names></name><name name-style="western"><surname>Roux</surname><given-names>S</given-names></name><name name-style="western"><surname>Mngadi</surname><given-names>K</given-names></name><name name-style="western"><surname>Innes</surname><given-names>C</given-names></name><name name-style="western"><surname>Mathebula</surname><given-names>M</given-names></name><name name-style="western"><surname>Allen</surname><given-names>M</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>M</given-names></name><name name-style="western"><surname>Kublin</surname><given-names>J</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L</given-names></name><collab>HVTN 503, Phambili study team</collab></person-group><article-title>Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><fpage>388</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70020-9</pub-id><pub-id pub-id-type="pmid">24560541</pub-id><pub-id pub-id-type="pmcid">PMC4174314</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>G</given-names></name><name name-style="western"><surname>Buchbinder</surname><given-names>S</given-names></name><name name-style="western"><surname>Duerr</surname><given-names>A</given-names></name></person-group><article-title>Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine</article-title><source>Curr Opin HIV AIDS</source><year>2010</year><volume>5</volume><fpage>357</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1097/COH.0b013e32833d2d2b</pub-id><pub-id pub-id-type="pmid">20978374</pub-id><pub-id pub-id-type="pmcid">PMC2995949</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Excler</surname><given-names>JL</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaewkungwal</surname><given-names>J</given-names></name><name name-style="western"><surname>Premsri</surname><given-names>N</given-names></name><name name-style="western"><surname>Kunasol</surname><given-names>P</given-names></name><name name-style="western"><surname>Karasavvas</surname><given-names>N</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>A</given-names></name><name name-style="western"><surname>Ngauy</surname><given-names>V</given-names></name><name name-style="western"><surname>Sinangil</surname><given-names>F</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>P</given-names></name><name name-style="western"><surname>deCamp</surname><given-names>AC</given-names></name><name name-style="western"><surname>Phogat</surname><given-names>S</given-names></name><name name-style="western"><surname>Garunathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>J</given-names></name><name name-style="western"><surname>DiazGranados</surname><given-names>C</given-names></name><name name-style="western"><surname>Ratto-Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Pegu</surname><given-names>P</given-names></name><name name-style="western"><surname>Eller</surname><given-names>M</given-names></name><name name-style="western"><surname>Karnasuta</surname><given-names>C</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>S</given-names></name><name name-style="western"><surname>Vandergrift</surname><given-names>N</given-names></name><name name-style="western"><surname>Wills</surname><given-names>S</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><name name-style="western"><surname>Michael</surname><given-names>NL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Vasan</surname><given-names>S</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>RJ</given-names></name><collab>RV305 Study Team</collab></person-group><article-title>Randomized, Double-Blind Evaluation of Late Boost Strategies for&#160;HIV-Uninfected&#160;Vaccine&#160;Recipients in the&#160;RV144&#160;HIV&#160;Vaccine&#160;Efficacy Trial</article-title><source>J Infect Dis.</source><year>2017</year><volume>215</volume><fpage>1255</fpage><lpage>1263</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix09</pub-id><pub-id pub-id-type="pmid">28329190</pub-id><pub-id pub-id-type="pmcid">PMC5853427</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lenberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies</article-title><source>Virus Res</source><year>2018</year><volume>243</volume><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2017.10.011</pub-id><pub-id pub-id-type="pmid">29051051</pub-id><pub-id pub-id-type="pmcid">PMC7114535</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelsoe</surname><given-names>G</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name></person-group><article-title>Host controls of HIV broadly neutralizing antibody development</article-title><source>Immunol Rev</source><year>2017</year><volume>275</volume><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/imr.12508</pub-id><pub-id pub-id-type="pmid">28133807</pub-id><pub-id pub-id-type="pmcid">PMC5479487</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoot</surname><given-names>S</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>KW</given-names></name><name name-style="western"><surname>Strong</surname><given-names>RK</given-names></name><name name-style="western"><surname>Hangartner</surname><given-names>L</given-names></name><name name-style="western"><surname>Klein</surname><given-names>F</given-names></name><name name-style="western"><surname>Diskin</surname><given-names>R</given-names></name><name name-style="western"><surname>Scheid</surname><given-names>JF</given-names></name><name name-style="western"><surname>Sather</surname><given-names>DN</given-names></name><name name-style="western"><surname>Burton</surname><given-names>DR</given-names></name><name name-style="western"><surname>Stamatatos</surname><given-names>L</given-names></name></person-group><article-title>Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs</article-title><source>PLoS Pathog</source><year>2013</year><volume>9</volume><fpage>e1003106</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003106</pub-id><pub-id pub-id-type="pmid">23300456</pub-id><pub-id pub-id-type="pmcid">PMC3536657</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lippy</surname><given-names>A</given-names></name><name name-style="western"><surname>Stamatatos</surname><given-names>L</given-names></name></person-group><article-title>Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447&#8211;52D</article-title><source>J Virol</source><year>2014</year><volume>88</volume><fpage>2645</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1128/JVI.03228-13</pub-id><pub-id pub-id-type="pmid">24352455</pub-id><pub-id pub-id-type="pmcid">PMC3958080</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonsignori</surname><given-names>M</given-names></name><name name-style="western"><surname>Liao</surname><given-names>HX</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F</given-names></name><name name-style="western"><surname>Williams</surname><given-names>WB</given-names></name><name name-style="western"><surname>Alam</surname><given-names>SM</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>BF</given-names></name></person-group><article-title>Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development</article-title><source>Immunol Rev</source><year>2017</year><volume>275</volume><fpage>145</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1111/imr.12509</pub-id><pub-id pub-id-type="pmid">28133802</pub-id><pub-id pub-id-type="pmcid">PMC5302796</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></name></person-group><article-title>Targeting broadly neutralizing antibody precursors: a na&#239;ve approach to vaccine design</article-title><source>Curr Opin HIV AIDS</source><year>2019</year><volume>14</volume><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000548</pub-id><pub-id pub-id-type="pmid">30946041</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burton</surname><given-names>DR</given-names></name><name name-style="western"><surname>Hangartner</surname><given-names>L</given-names></name></person-group><article-title>Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design</article-title><source>Annual Review of Immunology</source><year>2016</year><volume>34</volume><fpage>635</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-041015-055515</pub-id><pub-id pub-id-type="pmid">27168247</pub-id><pub-id pub-id-type="pmcid">PMC6034635</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barouch</surname><given-names>DH</given-names></name><name name-style="western"><surname>O'Brien</surname><given-names>KL</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>NL</given-names></name><name name-style="western"><surname>King</surname><given-names>SL</given-names></name><name name-style="western"><surname>Abbink</surname><given-names>P</given-names></name><name name-style="western"><surname>Maxfield</surname><given-names>LF</given-names></name><name name-style="western"><surname>Sun</surname><given-names>YH</given-names></name><name name-style="western"><surname>La Porte</surname><given-names>A</given-names></name><name name-style="western"><surname>Riggs</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>DM</given-names></name><name name-style="western"><surname>Clark</surname><given-names>SL</given-names></name><name name-style="western"><surname>Backus</surname><given-names>K</given-names></name><name name-style="western"><surname>Perry</surname><given-names>JR</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Carville</surname><given-names>A</given-names></name><name name-style="western"><surname>Mansfield</surname><given-names>KG</given-names></name><name name-style="western"><surname>Szinger</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>W</given-names></name><name name-style="western"><surname>Muldoon</surname><given-names>M</given-names></name><name name-style="western"><surname>Korber</surname><given-names>B</given-names></name></person-group><article-title>Mosaic&#160;HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><fpage>319</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/nm.2089</pub-id><pub-id pub-id-type="pmid">20173752</pub-id><pub-id pub-id-type="pmcid">PMC2834868</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><name name-style="western"><surname>Finak</surname><given-names>G</given-names></name><name name-style="western"><surname>Ushey</surname><given-names>K</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>C</given-names></name><name name-style="western"><surname>Hawn</surname><given-names>TR</given-names></name><name name-style="western"><surname>Frahm</surname><given-names>N</given-names></name><name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Mahomed</surname><given-names>H</given-names></name><name name-style="western"><surname>Hanekom</surname><given-names>W</given-names></name><name name-style="western"><surname>Bart</surname><given-names>PA</given-names></name><name name-style="western"><surname>Pantaleo</surname><given-names>G</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>GD</given-names></name><name name-style="western"><surname>Rerks-Ngarm</surname><given-names>S</given-names></name><name name-style="western"><surname>Kaewkungwal</surname><given-names>J</given-names></name><name name-style="western"><surname>Nitayaphan</surname><given-names>S</given-names></name><name name-style="western"><surname>Pitisuttithum</surname><given-names>P</given-names></name><name name-style="western"><surname>Michael</surname><given-names>NL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Robb</surname><given-names>ML</given-names></name><name name-style="western"><surname>O'Connell</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Karasavvas</surname><given-names>N</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>P</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>C</given-names></name><name name-style="western"><surname>S, McElrath MJ, Gottardo R, </surname></name></person-group><article-title>COMPASS identifies T-cell subsets correlated with clinical outcomes</article-title><source>Nat Biotechnol</source><year>2015</year><volume>33</volume><fpage>610</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/nbt.3187</pub-id><pub-id pub-id-type="pmid">26006008</pub-id><pub-id pub-id-type="pmcid">PMC4569006</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Excler</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Novel prime-boost vaccine strategies against&#160;HIV-1</article-title><source>Expert Rev Vaccin</source><year>2019</year><volume>18</volume><fpage>765</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1080/14760584.2019.1640117</pub-id><pub-id pub-id-type="pmid">31271322</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chertova</surname><given-names>E</given-names></name><name name-style="western"><surname>Chertov</surname><given-names>O</given-names></name><name name-style="western"><surname>Coren</surname><given-names>LV</given-names></name><name name-style="western"><surname>Roser</surname><given-names>JD</given-names></name><name name-style="western"><surname>Trubey</surname><given-names>CM</given-names></name><name name-style="western"><surname>Bess</surname><given-names>JW</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Sowder</surname><given-names>RC</given-names><suffix>2nd</suffix></name><name name-style="western"><surname>Barsov</surname><given-names>E</given-names></name><name name-style="western"><surname>Hood</surname><given-names>BL</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages</article-title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>9039</fpage><lpage>9052</lpage><pub-id pub-id-type="doi">10.1128/JVI.01013-06</pub-id><pub-id pub-id-type="pmid">16940516</pub-id><pub-id pub-id-type="pmcid">PMC1563931</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrich</surname><given-names>D</given-names></name><name name-style="western"><surname>Ulich</surname><given-names>C</given-names></name><name name-style="western"><surname>Garc&#237;a-Mart&#237;nez</surname><given-names>LF</given-names></name><name name-style="western"><surname>Gaynor</surname><given-names>RB</given-names></name></person-group><article-title>Tat is required for efficient HIV-1 reverse transcription</article-title><source>EMBO J</source><year>1997</year><volume>16</volume><fpage>1224</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.6.1224</pub-id><pub-id pub-id-type="pmid">9135139</pub-id><pub-id pub-id-type="pmcid">PMC1169721</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchi&#242;</surname><given-names>S</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>M</given-names></name><name name-style="western"><surname>Primo</surname><given-names>L</given-names></name><name name-style="western"><surname>Gramaglia</surname><given-names>D</given-names></name><name name-style="western"><surname>Butini</surname><given-names>L</given-names></name><name name-style="western"><surname>Gennero</surname><given-names>L</given-names></name><name name-style="western"><surname>De Vivo</surname><given-names>E</given-names></name><name name-style="western"><surname>Arap</surname><given-names>W</given-names></name><name name-style="western"><surname>Giacca</surname><given-names>M</given-names></name><name name-style="western"><surname>Pasqualini</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein</article-title><source>Blood</source><year>2005</year><volume>105</volume><fpage>2802</fpage><lpage>2811</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-06-2212</pub-id><pub-id pub-id-type="pmid">15591114</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>IK</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>VA</given-names></name><name name-style="western"><surname>Andreini</surname><given-names>C</given-names></name><name name-style="western"><surname>Chiozzini</surname><given-names>C</given-names></name><name name-style="western"><surname>Ferrantelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Cossut</surname><given-names>MR</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><etal/></person-group><article-title>HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e48781</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0048781</pub-id><pub-id pub-id-type="pmid">23152803</pub-id><pub-id pub-id-type="pmcid">PMC3496724</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>JW</given-names></name></person-group><article-title>Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA</article-title><source>Science</source><year>2001</year><volume>293</volume><fpage>1503</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1126/science.1061548</pub-id><pub-id pub-id-type="pmid">11520990</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bohan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kashanchi</surname><given-names>F</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>L</given-names></name><name name-style="western"><surname>Boris-Lawrie</surname><given-names>KA</given-names></name><name name-style="western"><surname>Brady</surname><given-names>JN</given-names></name></person-group><article-title>Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro</article-title><source>Gene Expr</source><year>1992</year><volume>2</volume><fpage>391</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">1282057</pub-id><pub-id pub-id-type="pmcid">PMC6057369</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>AT</given-names></name><name name-style="western"><surname>Harwig</surname><given-names>A</given-names></name><name name-style="western"><surname>Berkhout</surname><given-names>B</given-names></name></person-group><article-title>The HIV-1 Tat protein has a versatile role in activating viral transcription</article-title><source>J Virol</source><year>2011</year><volume>85</volume><fpage>9506</fpage><lpage>9516</lpage><pub-id pub-id-type="doi">10.1128/JVI.00650-11</pub-id><pub-id pub-id-type="pmid">21752913</pub-id><pub-id pub-id-type="pmcid">PMC3165771</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feinberg</surname><given-names>MB</given-names></name><name name-style="western"><surname>Baltimore</surname><given-names>D</given-names></name><name name-style="western"><surname>Frankel</surname><given-names>AD</given-names></name></person-group><article-title>The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>4045</fpage><lpage>4049</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.9.4045</pub-id><pub-id pub-id-type="pmid">2023953</pub-id><pub-id pub-id-type="pmcid">PMC51590</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberger</surname><given-names>LS</given-names></name><name name-style="western"><surname>Burnett</surname><given-names>JC</given-names></name><name name-style="western"><surname>Toettcher</surname><given-names>JE</given-names></name><name name-style="western"><surname>Arkin</surname><given-names>AP</given-names></name><name name-style="western"><surname>Schaffer</surname><given-names>DV</given-names></name></person-group><article-title>Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>169</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.06.006</pub-id><pub-id pub-id-type="pmid">16051143</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Razooky</surname><given-names>BS</given-names></name><name name-style="western"><surname>Pai</surname><given-names>A</given-names></name><name name-style="western"><surname>Aull</surname><given-names>K</given-names></name><name name-style="western"><surname>Rouzine</surname><given-names>IM</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>SL</given-names></name></person-group><article-title>A Hardwired HIV Latency Program</article-title><source> Cell</source><year>2015</year><volume>160</volume><fpage>990</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.02.009</pub-id><pub-id pub-id-type="pmid">25723172</pub-id><pub-id pub-id-type="pmcid">PMC4395878</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howcroft</surname><given-names>TK</given-names></name><name name-style="western"><surname>Strebel</surname><given-names>K</given-names></name><name name-style="western"><surname>Martin</surname><given-names>MA</given-names></name><name name-style="western"><surname>Singer</surname><given-names>DS</given-names></name></person-group><article-title>Repression of MHC class I gene promoter activity by two-exon Tat of HIV</article-title><source>Science</source><year>1993</year><volume>260</volume><fpage>1320</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1126/science.8493575</pub-id><pub-id pub-id-type="pmid">8493575</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanazawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Peterlin</surname><given-names>BM</given-names></name></person-group><article-title>Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection</article-title><source>Immunity</source><year>2000</year><volume>12</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80159-4</pub-id><pub-id pub-id-type="pmid">10661406</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izmailova</surname><given-names>E</given-names></name><name name-style="western"><surname>Bertley</surname><given-names>FMN</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages</article-title><source>Nat Med</source><year>2003</year><volume>9</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/nm822</pub-id><pub-id pub-id-type="pmid">12539042</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>L</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wingfield</surname><given-names>P</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name></person-group><article-title>Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation</article-title><source>J Virol</source><year>1993</year><volume>67</volume><fpage>277</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1128/JVI.67.1.277-287.1993</pub-id><pub-id pub-id-type="pmid">8416373</pub-id><pub-id pub-id-type="pmcid">PMC237361</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>HC</given-names></name><name name-style="western"><surname>Samaniego</surname><given-names>F</given-names></name><name name-style="western"><surname>Nair</surname><given-names>BC</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>L</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region</article-title><source>AIDS</source><year>1997</year><volume>11</volume><fpage>1421</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1097/00002030-199712000-00006</pub-id><pub-id pub-id-type="pmid">9342064</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayne</surname><given-names>F</given-names></name><name name-style="western"><surname>Debaisieux</surname><given-names>S</given-names></name><name name-style="western"><surname>Yezid</surname><given-names>H</given-names></name><name name-style="western"><surname>Lin</surname><given-names>YL</given-names></name><name name-style="western"><surname>Mettling</surname><given-names>C</given-names></name><name name-style="western"><surname>Konate</surname><given-names>K</given-names></name><name name-style="western"><surname>Chazal</surname><given-names>N</given-names></name><name name-style="western"><surname>Arold</surname><given-names>ST</given-names></name><name name-style="western"><surname>Pugni&#232;re</surname><given-names>M</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>F</given-names></name><etal/></person-group><article-title>Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells</article-title><source>EMBO J</source><year>2010</year><volume>29</volume><fpage>1348</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1038/emboj.2010.32</pub-id><pub-id pub-id-type="pmid">20224549</pub-id><pub-id pub-id-type="pmcid">PMC2868572</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Salahuddin</surname><given-names>SZ</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name><name name-style="western"><surname>Wong-Staal</surname><given-names>F</given-names></name></person-group><article-title>Tat protein of HIV-1 stimulates growth of cells derived from Kaposi&#8217;s sarcoma lesions of AIDS patients</article-title><source>Nature</source><year>1990</year><volume>345</volume><fpage>84</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1038/345084a0</pub-id><pub-id pub-id-type="pmid">2184372</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Markham</surname><given-names>P</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Colombini</surname><given-names>S</given-names></name><name name-style="western"><surname>Raffeld</surname><given-names>M</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HK</given-names></name><name name-style="western"><surname>Brady</surname><given-names>JN</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name></person-group><article-title>Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi&#8217;s sarcoma</article-title><source>Nature</source><year>1994</year><volume>371</volume><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/371674a0</pub-id><pub-id pub-id-type="pmid">7935812</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence</article-title><source>Proc Natl Acad Sci U S A</source><year>1993</year><pub-id pub-id-type="doi">10.1073/pnas.90.17.7941</pub-id><pub-id pub-id-type="pmid">7690138</pub-id><pub-id pub-id-type="pmcid">PMC47263</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albini</surname><given-names>A</given-names></name><name name-style="western"><surname>Ferrini</surname><given-names>S</given-names></name><name name-style="western"><surname>Benelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Sforzini</surname><given-names>S</given-names></name><name name-style="western"><surname>Giunciuglio</surname><given-names>D</given-names></name><name name-style="western"><surname>Aluigi</surname><given-names>MG</given-names></name><name name-style="western"><surname>Proudfoot</surname><given-names>AE</given-names></name><name name-style="western"><surname>Alouani</surname><given-names>S</given-names></name><name name-style="western"><surname>Wells</surname><given-names>TN</given-names></name><name name-style="western"><surname>Mariani</surname><given-names>G</given-names></name><etal/></person-group><article-title>HIV-1 Tat protein mimicry of chemokines</article-title><source>Proc Natl Acad Sci USA</source><year>1998</year><volume>95</volume><fpage>13153</fpage><lpage>13158</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.22.13153</pub-id><pub-id pub-id-type="pmid">9789057</pub-id><pub-id pub-id-type="pmcid">PMC23742</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fanales-Belasio</surname><given-names>E</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Nappi</surname><given-names>F</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Micheletti</surname><given-names>F</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.1.197</pub-id><pub-id pub-id-type="pmid">11751963</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Palladino</surname><given-names>C</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Falchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Pavone Cossut</surname><given-names>MR</given-names></name><name name-style="western"><surname>Campagna</surname><given-names>M</given-names></name><name name-style="western"><surname>Arancio</surname><given-names>A</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Andreini</surname><given-names>C</given-names></name><name name-style="western"><surname>Banci</surname><given-names>L</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication</article-title><source>Int J Mol Sci</source><year>2020</year><volume>22</volume><fpage>E317</fpage><pub-id pub-id-type="doi">10.3390/ijms22010317</pub-id><pub-id pub-id-type="pmid">33396807</pub-id><pub-id pub-id-type="pmcid">PMC7796023</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>TP</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>KR</given-names></name><name name-style="western"><surname>Maric</surname><given-names>D</given-names></name><name name-style="western"><surname>Calabresi</surname><given-names>PA</given-names></name><name name-style="western"><surname>Hasbun</surname><given-names>R</given-names></name><name name-style="western"><surname>Nath</surname><given-names>A</given-names></name></person-group><article-title>Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein</article-title><source>Proc Natl Acad Sci USA</source><year>2013</year><volume>110</volume><fpage>13588</fpage><lpage>13593</lpage><pub-id pub-id-type="doi">10.1073/pnas.1308673110</pub-id><pub-id pub-id-type="pmid">23898208</pub-id><pub-id pub-id-type="pmcid">PMC3746932</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>I</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>W</given-names></name><name name-style="western"><surname>Sodroski</surname><given-names>J</given-names></name><name name-style="western"><surname>Pardee</surname><given-names>AB</given-names></name></person-group><article-title>Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains</article-title><source>J. Virol</source><year>1998</year><volume>72</volume><fpage>8952</fpage><lpage>8960</lpage><pub-id pub-id-type="doi">10.1128/JVI.72.11.8952-8960.1998</pub-id><pub-id pub-id-type="pmid">9765440</pub-id><pub-id pub-id-type="pmcid">PMC110312</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>H</given-names></name><name name-style="western"><surname>Neuveut</surname><given-names>C</given-names></name><name name-style="western"><surname>Tiffany</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Selective CXCR4 antagonism by Tat: Implications for&#160;in vivo&#160;expansion of coreceptor use by HIV-1</article-title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>11466</fpage><lpage>11471</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.21.11466</pub-id><pub-id pub-id-type="pmid">11027346</pub-id><pub-id pub-id-type="pmcid">PMC17223</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shi</surname><given-names>B</given-names></name><name name-style="western"><surname>Borodyansky</surname><given-names>L</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Pardee</surname><given-names>AB</given-names></name></person-group><article-title>Tat protein induces self-perpetuating permissivity for productive HIV-1 infection</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>8116</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.15.8116</pub-id><pub-id pub-id-type="pmid">9223324</pub-id><pub-id pub-id-type="pmcid">PMC21566</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fanales-Belasio</surname><given-names>E</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Pavone Cossut</surname><given-names>MR</given-names></name><name name-style="western"><surname>Scoglio</surname><given-names>A</given-names></name><name name-style="western"><surname>Collacchi</surname><given-names>B</given-names></name><name name-style="western"><surname>Nappi</surname><given-names>F</given-names></name><name name-style="western"><surname>Macchia</surname><given-names>I</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><etal/></person-group><article-title>HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection</article-title><source>J Immunol</source><year>2009</year><volume>182</volume><fpage>2888</fpage><lpage>2897</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0711406</pub-id><pub-id pub-id-type="pmid">19234184</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buonaguro</surname><given-names>L</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HK</given-names></name><name name-style="western"><surname>Bohan</surname><given-names>CA</given-names></name><name name-style="western"><surname>Kao</surname><given-names>V</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>R</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines</article-title><source>J Virol</source><year>1992</year><volume>66</volume><fpage>7159</fpage><lpage>7167</lpage><pub-id pub-id-type="doi">10.1128/JVI.66.12.7159-7167.1992</pub-id><pub-id pub-id-type="pmid">1279199</pub-id><pub-id pub-id-type="pmcid">PMC240407</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scala</surname><given-names>G</given-names></name><name name-style="western"><surname>Ruocco</surname><given-names>MR</given-names></name><name name-style="western"><surname>Ambrosino</surname><given-names>C</given-names></name><name name-style="western"><surname>Mallardo</surname><given-names>M</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>V</given-names></name><name name-style="western"><surname>Baldassarre</surname><given-names>F</given-names></name><name name-style="western"><surname>Dragonetti</surname><given-names>E</given-names></name><name name-style="western"><surname>Quinto</surname><given-names>I</given-names></name><name name-style="western"><surname>Venuta</surname><given-names>S</given-names></name></person-group><article-title>The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein</article-title><source>J Exp Med</source><year>1994</year><volume>179</volume><fpage>961</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1084/jem.179.3.961</pub-id><pub-id pub-id-type="pmid">8113688</pub-id><pub-id pub-id-type="pmcid">PMC2191426</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lafrenie</surname><given-names>RM</given-names></name><name name-style="western"><surname>Wahl</surname><given-names>LM</given-names></name><name name-style="western"><surname>Epstein</surname><given-names>JS</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>KM</given-names></name><name name-style="western"><surname>Dhawan</surname><given-names>S</given-names></name></person-group><article-title>Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression</article-title><source>J Immunol</source><year>1997</year><volume>159</volume><fpage>4077</fpage><lpage>4083</lpage><pub-id pub-id-type="pmid">9378998</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ben Haij</surname><given-names>N</given-names></name><name name-style="western"><surname>Plan&#232;s</surname><given-names>R</given-names></name><name name-style="western"><surname>Leghmari</surname><given-names>K</given-names></name><name name-style="western"><surname>Serrero</surname><given-names>M</given-names></name><name name-style="western"><surname>Delobel</surname><given-names>P</given-names></name><name name-style="western"><surname>Izopet</surname><given-names>J</given-names></name><name name-style="western"><surname>BenMohamed</surname><given-names>L</given-names></name><name name-style="western"><surname>Bahraoui</surname><given-names>E</given-names></name></person-group><article-title>HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF-&#954;B Pathway</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0129425</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0129425</pub-id><pub-id pub-id-type="pmid">26090662</pub-id><pub-id pub-id-type="pmcid">PMC4474861</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plan&#232;s</surname><given-names>R</given-names></name><name name-style="western"><surname>Ben Haij</surname><given-names>N</given-names></name><name name-style="western"><surname>Leghmari</surname><given-names>K</given-names></name><name name-style="western"><surname>Serrero</surname><given-names>M</given-names></name><name name-style="western"><surname>BenMohamed</surname><given-names>L</given-names></name><name name-style="western"><surname>Bahraoui</surname><given-names>E</given-names></name></person-group><article-title>HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes</article-title><source>J Virol</source><year>2016</year><volume>90</volume><fpage>5886</fpage><lpage>5898</lpage><pub-id pub-id-type="doi">10.1128/JVI.00262-16</pub-id><pub-id pub-id-type="pmid">27053552</pub-id><pub-id pub-id-type="pmcid">PMC4907244</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiozzini</surname><given-names>C</given-names></name><name name-style="western"><surname>Collacchi</surname><given-names>B</given-names></name><name name-style="western"><surname>Nappi</surname><given-names>F</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T</given-names></name><name name-style="western"><surname>Arenaccio</surname><given-names>C</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><etal/></person-group><article-title>Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>2189</fpage><lpage>2200</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000389</pub-id><pub-id pub-id-type="pmid">25313583</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jordan</surname><given-names>A</given-names></name><name name-style="western"><surname>Bisgrove</surname><given-names>B</given-names></name><name name-style="western"><surname>Verdin</surname><given-names>E</given-names></name></person-group><article-title>HIV reproducibly establishes latent infection after acute infection of T cells in vitro</article-title><source>EMBO J</source><year>2003</year><volume>22</volume><fpage>1868</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg188</pub-id><pub-id pub-id-type="pmid">12682019</pub-id><pub-id pub-id-type="pmcid">PMC154479</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahabieh</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ooms</surname><given-names>M</given-names></name><name name-style="western"><surname>Simon</surname><given-names>V</given-names></name><name name-style="western"><surname>Sadowski</surname><given-names>I</given-names></name></person-group><article-title>A doubly fluorescent hiv-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>4716</fpage><lpage>4727</lpage><pub-id pub-id-type="doi">10.1128/JVI.03478-12</pub-id><pub-id pub-id-type="pmid">23408629</pub-id><pub-id pub-id-type="pmcid">PMC3624398</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavez</surname><given-names>L</given-names></name><name name-style="western"><surname>Calvanese</surname><given-names>V</given-names></name><name name-style="western"><surname>Verdin</surname><given-names>E</given-names></name></person-group><article-title>HIV latency is established directly and early in both resting and activated CD4 T cells</article-title><source>Plos Pathog</source><year>2015</year><volume>11</volume><fpage>e1004955</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004955</pub-id><pub-id pub-id-type="pmid">26067822</pub-id><pub-id pub-id-type="pmcid">PMC4466167</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinberger</surname><given-names>AD</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>LS</given-names></name></person-group><article-title>Stochastic fate selection in HIV-infected patients</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>499</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.09.039</pub-id><pub-id pub-id-type="pmid">24243007</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosmane</surname><given-names>NN</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Bruner</surname><given-names>KM</given-names></name><name name-style="western"><surname>Capoferri</surname><given-names>AA</given-names></name><name name-style="western"><surname>Beg</surname><given-names>S</given-names></name><name name-style="western"><surname>Rosenbloom</surname><given-names>DI</given-names></name><name name-style="western"><surname>Keele</surname><given-names>BF</given-names></name><name name-style="western"><surname>Ho</surname><given-names>YC</given-names></name><name name-style="western"><surname>Siliciano</surname><given-names>JD</given-names></name><name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>Proliferation of latently infected CD4+ T cells carrying replication-competent HIV</article-title><source>J Exp Med</source><year>2017</year><volume>214</volume><fpage>959</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1084/jem.20170193</pub-id><pub-id pub-id-type="pmid">28341641</pub-id><pub-id pub-id-type="pmcid">PMC5379987</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinkevych</surname><given-names>M</given-names></name><name name-style="western"><surname>Cromer</surname><given-names>D</given-names></name><name name-style="western"><surname>Tolstrup</surname><given-names>M</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>SR</given-names></name><name name-style="western"><surname>S&#248;gaard</surname><given-names>OS</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>TA</given-names></name><name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kelleher</surname><given-names>AD</given-names></name></person-group><article-title>Davenport MP (2015) HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5&#8211;8 Days Implications for HIV Remission</article-title><source>PLoS Pathog</source><year>2015</year><volume>11</volume><fpage>e1005000</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005745</pub-id><pub-id pub-id-type="pmid">26133551</pub-id><pub-id pub-id-type="pmcid">PMC4489624</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zerbato</surname><given-names>JM</given-names></name><name name-style="western"><surname>Purves</surname><given-names>HV</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>SR</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>TA</given-names></name></person-group><article-title>Between a shock and a hard place: challenges and developments in HIV latency reversal</article-title><source>Curr Opin Virol</source><year>2019</year><volume>38</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.coviro.2019.03.004</pub-id><pub-id pub-id-type="pmid">31048093</pub-id><pub-id pub-id-type="pmcid">PMC6819240</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moranguinho</surname><given-names>I</given-names></name><name name-style="western"><surname>Valente</surname><given-names>ST</given-names></name></person-group><article-title>Block-And-Lock: New Horizons for a Cure for HIV-1</article-title><source>Viruses</source><year>2020</year><volume>12</volume><fpage>1443</fpage><pub-id pub-id-type="doi">10.3390/v12121443</pub-id><pub-id pub-id-type="pmcid">PMC7765451</pub-id><pub-id pub-id-type="pmid">33334019</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sengupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>Targeting the Latent Reservoir for HIV-1</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>872</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.04.030</pub-id><pub-id pub-id-type="pmid">29768175</pub-id><pub-id pub-id-type="pmcid">PMC6196732</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aamer</surname><given-names>HA</given-names></name><name name-style="western"><surname>McClure</surname><given-names>J</given-names></name><name name-style="western"><surname>Ko</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment</article-title><source>Plos Pathog</source><year>2020</year><volume>16</volume><fpage>e1008791</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1008791</pub-id><pub-id pub-id-type="pmid">32841299</pub-id><pub-id pub-id-type="pmcid">PMC7473585</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Sforza</surname><given-names>F</given-names></name><name name-style="western"><surname>Finessi</surname><given-names>V</given-names></name><name name-style="western"><surname>Chachage</surname><given-names>M</given-names></name><name name-style="western"><surname>Geldmacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name></person-group><article-title>The HIV-1 Tat protein affects human CD4+ T-cell programming and activation, and favors the differentiation of na&#239;ve CD4+ T cells</article-title><source>AIDS</source><year>2018</year><volume>32</volume><fpage>575</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001734</pub-id><pub-id pub-id-type="pmid">29280760</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>X</given-names></name><name name-style="western"><surname>Irwin</surname><given-names>D</given-names></name><name name-style="western"><surname>Kanazawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Romeo</surname><given-names>J</given-names></name><name name-style="western"><surname>Yen</surname><given-names>TS</given-names></name><name name-style="western"><surname>Peterlin</surname><given-names>BM</given-names></name></person-group><article-title>Transcriptional profiles of latent human immunodeficiency virus in infected individuals: Effects of Tat on the host and reservoir</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>8227</fpage><lpage>8236</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.15.8227-8236.2003</pub-id><pub-id pub-id-type="pmid">12857891</pub-id><pub-id pub-id-type="pmcid">PMC165222</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Francavilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Marcotullio</surname><given-names>S</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Paniccia</surname><given-names>G</given-names></name><name name-style="western"><surname>Scoglio</surname><given-names>A</given-names></name><etal/></person-group><article-title>Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><fpage>e13540</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0013540</pub-id><pub-id pub-id-type="pmid">21085635</pub-id><pub-id pub-id-type="pmcid">PMC2978690</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Casabianca</surname><given-names>A</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Francavilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><etal/></person-group><article-title>HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial</article-title><source>Retrovirology</source><year>2015</year><volume>12</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/s12977-015-0151-y</pub-id><pub-id pub-id-type="pmid">25924841</pub-id><pub-id pub-id-type="pmcid">PMC4414440</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kieffer</surname><given-names>TL</given-names></name><name name-style="western"><surname>Finucane</surname><given-names>MM</given-names></name><name name-style="western"><surname>Nettles</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads</article-title><source>J Infect Dis</source><year>2004</year><volume>189</volume><fpage>1452</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1086/382488</pub-id><pub-id pub-id-type="pmid">15073683</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kearney</surname><given-names>MF</given-names></name><name name-style="western"><surname>Spindler</surname><given-names>J</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W</given-names></name><etal/></person-group><article-title>Lack of detectable hiv-1 molecular evolution during suppressive antiretroviral therapy</article-title><source>PLoS Pathog</source><year>2014</year><volume>10</volume><fpage>e1004010</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004010</pub-id><pub-id pub-id-type="pmid">24651464</pub-id><pub-id pub-id-type="pmcid">PMC3961343</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><mixed-citation publication-type="other">Brodin J, Zanini F, Thebo L, et al. (2016) Establishment and stability of the latent HIV-1 DNA reservoir. eLife 5: e18889. 10.7554/eLife.18889<pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.18889</pub-id><pub-id pub-id-type="pmcid">PMC5201419</pub-id><pub-id pub-id-type="pmid">27855060</pub-id></mixed-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Zyl</surname><given-names>GU</given-names></name><name name-style="western"><surname>Katusiime</surname><given-names>MG</given-names></name><name name-style="western"><surname>Wiegand</surname><given-names>A</given-names></name><etal/></person-group><article-title>No evidence of HIV replication in children on antiretroviral therapy</article-title><source>J Clin Invest</source><year>2017</year><volume>127</volume><fpage>3827</fpage><lpage>3834</lpage><pub-id pub-id-type="doi">10.1172/JCI94582</pub-id><pub-id pub-id-type="pmid">28891813</pub-id><pub-id pub-id-type="pmcid">PMC5617669</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McManus</surname><given-names>WR</given-names></name><name name-style="western"><surname>Bale</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Spindler</surname><given-names>J</given-names></name><etal/></person-group><article-title>HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy</article-title><source>J Clin Invest</source><year>2019</year><volume>129</volume><fpage>4629</fpage><lpage>4642</lpage><pub-id pub-id-type="doi">10.1172/JCI126714</pub-id><pub-id pub-id-type="pmid">31361603</pub-id><pub-id pub-id-type="pmcid">PMC6819093</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abrahams</surname><given-names>MR</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>SB</given-names></name><name name-style="western"><surname>Garrett</surname><given-names>N</given-names></name><etal/></person-group><article-title>The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation</article-title><source>Sci Transl Med</source><year>2019</year><pub-id pub-id-type="doi">10.1126/scitranslmed.aaw5589</pub-id><pub-id pub-id-type="pmid">31597754</pub-id><pub-id pub-id-type="pmcid">PMC7233356</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tobin</surname><given-names>NH</given-names></name><name name-style="western"><surname>Learn</surname><given-names>GH</given-names></name><name name-style="western"><surname>Holte</surname><given-names>SE</given-names></name><name name-style="western"><surname>at al. </surname></name></person-group><article-title>Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>9625</fpage><lpage>9634</lpage><pub-id pub-id-type="doi">10.1128/JVI.79.15.9625-9634.2005</pub-id><pub-id pub-id-type="pmid">16014925</pub-id><pub-id pub-id-type="pmcid">PMC1181593</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buz&#243;n</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Massanella</surname><given-names>M</given-names></name><name name-style="western"><surname>Llibre</surname><given-names>JM</given-names></name><etal/></person-group><article-title>HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><fpage>460</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/nm.2111</pub-id><pub-id pub-id-type="pmid">20228817</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatano</surname><given-names>H</given-names></name><name name-style="western"><surname>Strain</surname><given-names>MC</given-names></name><name name-style="western"><surname>Scherzer</surname><given-names>R</given-names></name></person-group><article-title>Increase in 2&#8211;Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial</article-title><source>J Infect Dis</source><year>2013</year><volume>208</volume><fpage>1436</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit453</pub-id><pub-id pub-id-type="pmid">23975885</pub-id><pub-id pub-id-type="pmcid">PMC3789577</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name><name name-style="western"><surname>Staskus</surname><given-names>K</given-names></name><name name-style="western"><surname>Wietgrefe</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Persistent HIV-1 replication in low drug concentration lymphatic tissues</article-title><source>Proc Natl Acad Sci USA</source><year>2014</year><volume>111</volume><fpage>2307</fpage><lpage>2312</lpage><pub-id pub-id-type="doi">10.1073/pnas.1318249111</pub-id><pub-id pub-id-type="pmid">24469825</pub-id><pub-id pub-id-type="pmcid">PMC3926074</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-Redondo</surname><given-names>R</given-names></name><name name-style="western"><surname>Fryer</surname><given-names>HR</given-names></name><name name-style="western"><surname>Bedford</surname><given-names>T</given-names></name><name name-style="western"><surname>Kim</surname><given-names>EY</given-names></name><name name-style="western"><surname>Archer</surname><given-names>J</given-names></name><name name-style="western"><surname>Pond</surname><given-names>SLK</given-names></name><name name-style="western"><surname>Chung</surname><given-names>YS</given-names></name><name name-style="western"><surname>Penugonda</surname><given-names>S</given-names></name><name name-style="western"><surname>Chipman</surname><given-names>J</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>CV</given-names></name><name name-style="western"><surname>Schacker</surname><given-names>TW</given-names></name><name name-style="western"><surname>Malim</surname><given-names>MH</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A</given-names></name><name name-style="western"><surname>Haase</surname><given-names>AT</given-names></name><name name-style="western"><surname>McLean</surname><given-names>AR</given-names></name><name name-style="western"><surname>Wolinsky</surname><given-names>SM</given-names></name></person-group><article-title>Persistent HIV-1 replication maintains the tissue reservoir during therapy</article-title><source>Nature</source><year>2016</year><volume>530</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nature16933</pub-id><pub-id pub-id-type="pmid">26814962</pub-id><pub-id pub-id-type="pmcid">PMC4865637</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>L</given-names></name><name name-style="western"><surname>Deng</surname><given-names>K</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><etal/></person-group><article-title>Transcriptional reprogramming during effector-to-memory transition renders CD4+ T cells permissive for latent HIV-1 infection</article-title><source>Immunity</source><year>2017</year><volume>47</volume><fpage>766</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.09.014</pub-id><pub-id pub-id-type="pmid">29045905</pub-id><pub-id pub-id-type="pmcid">PMC5948104</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#243;pez-Huertas</surname><given-names>MR</given-names></name><name name-style="western"><surname>Mateos</surname><given-names>E</given-names></name><name name-style="western"><surname>S&#225;nchez Del Cojo</surname><given-names>M</given-names></name><name name-style="western"><surname>G&#243;mez-Esquer</surname><given-names>F</given-names></name><name name-style="western"><surname>D&#237;az-Gil</surname><given-names>G</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Mora</surname><given-names>S</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>JA</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>E</given-names></name><name name-style="western"><surname>L&#243;pez-Campos</surname><given-names>G</given-names></name><name name-style="western"><surname>Alcam&#237;</surname><given-names>J</given-names></name><etal/></person-group><article-title>The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: A potential mechanism for persistent viral production</article-title><source>J Biol Chem</source><year>2013</year><volume>288</volume><fpage>7626</fpage><lpage>7644</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.408294</pub-id><pub-id pub-id-type="pmid">23364796</pub-id><pub-id pub-id-type="pmcid">PMC3597804</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Palladino</surname><given-names>C</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Taddeo</surname><given-names>B</given-names></name><name name-style="western"><surname>Toschi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma</article-title><source>Int J Vasc Med</source><year>2011</year><pub-id pub-id-type="doi">10.1155/2011/452729</pub-id><pub-id pub-id-type="pmid">22007303</pub-id><pub-id pub-id-type="pmcid">PMC3189568</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zauli</surname><given-names>G</given-names></name><name name-style="western"><surname>Gibellini</surname><given-names>D</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Bassini</surname><given-names>A</given-names></name><name name-style="western"><surname>Negrini</surname><given-names>M</given-names></name><name name-style="western"><surname>Monne</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazzoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Capitani</surname><given-names>S</given-names></name></person-group><article-title>The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells</article-title><source>Blood</source><year>1995</year><volume>86</volume><fpage>3823</fpage><lpage>3834</lpage><pub-id pub-id-type="doi">10.1182/blood.V86.10.3823.bloodjournal86103823</pub-id><pub-id pub-id-type="pmid">7579350</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S</given-names></name><name name-style="western"><surname>Alberto</surname><given-names>WDC</given-names></name><name name-style="western"><surname>Magat</surname><given-names>D</given-names></name><name name-style="western"><surname>Ahimovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>AB</given-names></name><name name-style="western"><surname>Durga</surname><given-names>R</given-names></name><name name-style="western"><surname>Chan</surname><given-names>D</given-names></name><name name-style="western"><surname>Zale</surname><given-names>E</given-names></name><name name-style="western"><surname>Mota</surname><given-names>TM</given-names></name><name name-style="western"><surname>Truong</surname><given-names>R</given-names></name><name name-style="western"><surname>Rohwetter</surname><given-names>T</given-names></name><name name-style="western"><surname>McCann</surname><given-names>CD</given-names></name><name name-style="western"><surname>Kovacs</surname><given-names>CM</given-names></name><name name-style="western"><surname>Benko</surname><given-names>E</given-names></name><name name-style="western"><surname>Wimpelberg</surname><given-names>A</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>C</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>WD</given-names></name><name name-style="western"><surname>Bosque</surname><given-names>A</given-names></name><name name-style="western"><surname>Bollard</surname><given-names>CM</given-names></name><name name-style="western"><surname>Jones</surname><given-names>RB</given-names></name></person-group><article-title>BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><fpage>2542</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1172/JCI13237</pub-id><pub-id pub-id-type="pmid">32027622</pub-id><pub-id pub-id-type="pmcid">PMC7191002</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zicari</surname><given-names>S</given-names></name><name name-style="western"><surname>Sessa</surname><given-names>L</given-names></name><name name-style="western"><surname>Cotugno</surname><given-names>N</given-names></name><name name-style="western"><surname>Ruggiero</surname><given-names>A</given-names></name><name name-style="western"><surname>Morrocchi</surname><given-names>E</given-names></name><name name-style="western"><surname>Concato</surname><given-names>C</given-names></name><name name-style="western"><surname>Rocca</surname><given-names>S</given-names></name><name name-style="western"><surname>Zangari</surname><given-names>P</given-names></name><name name-style="western"><surname>Manno</surname><given-names>EC</given-names></name><name name-style="western"><surname>Palma</surname><given-names>P</given-names></name></person-group><article-title>Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART</article-title><source>Viruses</source><year>2019</year><pub-id pub-id-type="doi">10.3390/v11030200</pub-id><pub-id pub-id-type="pmid">30818749</pub-id><pub-id pub-id-type="pmcid">PMC6466530</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deeks</surname><given-names>SG</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>SR</given-names></name><name name-style="western"><surname>Havlir</surname><given-names>DV</given-names></name></person-group><article-title>The end of AIDS: HIV infection as a chronic disease</article-title><source>Lancet</source><year>2013</year><volume>382</volume><fpage>1525</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)61809-7</pub-id><pub-id pub-id-type="pmid">24152939</pub-id><pub-id pub-id-type="pmcid">PMC4058441</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mediouni</surname><given-names>S</given-names></name><name name-style="western"><surname>Darque</surname><given-names>A</given-names></name><name name-style="western"><surname>Baillat</surname><given-names>G</given-names></name><name name-style="western"><surname>Ravaux</surname><given-names>I</given-names></name><name name-style="western"><surname>Dhiver</surname><given-names>C</given-names></name><name name-style="western"><surname>Tissot-Dupont</surname><given-names>H</given-names></name><name name-style="western"><surname>Mokhtari</surname><given-names>M</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>H</given-names></name><name name-style="western"><surname>Tamalet</surname><given-names>C</given-names></name><name name-style="western"><surname>Brunet</surname><given-names>C</given-names></name><name name-style="western"><surname>Paul</surname><given-names>P</given-names></name><name name-style="western"><surname>Dignat-George</surname><given-names>F</given-names></name><name name-style="western"><surname>Stein</surname><given-names>A</given-names></name><name name-style="western"><surname>Brouqui</surname><given-names>P</given-names></name><name name-style="western"><surname>Spector</surname><given-names>SA</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>GR</given-names></name><name name-style="western"><surname>Loret</surname><given-names>EP</given-names></name></person-group><article-title>Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein</article-title><source>Infect Disord Drug Targets</source><year>2012</year><volume>12</volume><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.2174/187152612798994939</pub-id><pub-id pub-id-type="pmid">22280310</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferdin</surname><given-names>J</given-names></name><name name-style="western"><surname>Gori&#269;ar</surname><given-names>K</given-names></name><name name-style="western"><surname>Dol&#382;an</surname><given-names>V</given-names></name><name name-style="western"><surname>Plemenita&#353;</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin</surname><given-names>JN</given-names></name><name name-style="western"><surname>Peterlin</surname><given-names>BM</given-names></name><name name-style="western"><surname>Deeks</surname><given-names>SG</given-names></name><name name-style="western"><surname>Lenassi</surname><given-names>M</given-names></name></person-group><article-title>Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>e0191613</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0191613</pub-id><pub-id pub-id-type="pmid">29364927</pub-id><pub-id pub-id-type="pmcid">PMC5783402</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigal</surname><given-names>A</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JT</given-names></name><name name-style="western"><surname>Balazs</surname><given-names>AB</given-names></name><name name-style="western"><surname>Dekel</surname><given-names>E</given-names></name><name name-style="western"><surname>Mayo</surname><given-names>A</given-names></name><name name-style="western"><surname>Milo</surname><given-names>R</given-names></name><name name-style="western"><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy</article-title><source>Nature</source><year>2011</year><volume>477</volume><fpage>95</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature10347</pub-id><pub-id pub-id-type="pmid">21849975</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cobucci</surname><given-names>RNO</given-names></name><name name-style="western"><surname>Lima</surname><given-names>PH</given-names></name><name name-style="western"><surname>Carvalho de Souza</surname><given-names>P</given-names></name><name name-style="western"><surname>Costa</surname><given-names>VV</given-names></name><etal/></person-group><article-title>Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review</article-title><source>J Infect Public Health</source><year>2015</year><volume>8</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2014.08.003</pub-id><pub-id pub-id-type="pmid">25294086</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Samaniego</surname><given-names>F</given-names></name><name name-style="western"><surname>Colombini</surname><given-names>S</given-names></name><name name-style="western"><surname>Manzari</surname><given-names>V</given-names></name><name name-style="western"><surname>Modesti</surname><given-names>A</given-names></name><name name-style="western"><surname>Nair</surname><given-names>BC</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>St&#252;rzl</surname><given-names>M</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>663</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">10397733</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Palladino</surname><given-names>C</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Morris</surname><given-names>CB</given-names></name><name name-style="western"><surname>Nair</surname><given-names>BC</given-names></name><name name-style="western"><surname>Markham</surname><given-names>P</given-names></name><name name-style="western"><surname>Nel</surname><given-names>A</given-names></name><name name-style="western"><surname>St&#252;rzl</surname><given-names>M</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin</article-title><source>J Immunol</source><year>1999</year><volume>163</volume><fpage>1929</fpage><lpage>1935</lpage><pub-id pub-id-type="pmid">10438928</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma</article-title><source>Clin Microbiol Rev</source><year>2002</year><volume>15</volume><fpage>310</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1128/cmr.15.2.310-326.2002</pub-id><pub-id pub-id-type="pmid">11932235</pub-id><pub-id pub-id-type="pmcid">PMC118071</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Samaniego</surname><given-names>F</given-names></name><name name-style="western"><surname>Markham</surname><given-names>PD</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi's sarcoma spindle cells</article-title><source>J Clin Invest</source><year>1995</year><volume>1995</volume><issue>95</issue><fpage>1723</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1172/JCI117849</pub-id><pub-id pub-id-type="pmcid">PMC295689</pub-id><pub-id pub-id-type="pmid">7535796</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Gendelman</surname><given-names>R</given-names></name><name name-style="western"><surname>Sirianni</surname><given-names>MC</given-names></name><name name-style="western"><surname>Chang</surname><given-names>HK</given-names></name><name name-style="western"><surname>Colombini</surname><given-names>S</given-names></name><name name-style="western"><surname>Markham</surname><given-names>PD</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Sonnabend</surname><given-names>J</given-names></name><name name-style="western"><surname>Pintus</surname><given-names>A</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>gamma-Interferon produced by CD8+ T cells infiltrating Kaposi's sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection?</article-title><source>Blood</source><year>1998</year><volume>91</volume><fpage>956</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">9446657</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Toschi</surname><given-names>E</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>St&#252;rzl</surname><given-names>M</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>1165</fpage><lpage>1170</lpage><pub-id pub-id-type="pmid">9916748</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>WS</given-names></name><name name-style="western"><surname>Lin</surname><given-names>TY</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>WW</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>TY</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>YT</given-names></name><name name-style="western"><surname>Chen</surname><given-names>ST</given-names></name><name name-style="western"><surname>Li</surname><given-names>WC</given-names></name><name name-style="western"><surname>Pan</surname><given-names>CC</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>M</given-names></name><name name-style="western"><surname>Yen</surname><given-names>CH</given-names></name><name name-style="western"><surname>Chen</surname><given-names>YA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>PC</given-names></name></person-group><article-title>HIV-1 Tat interacts with a Kaposi's sarcoma-associated Herpesvirus reactivation-upregulated antiangiogenic long noncoding RNA, LINC00313, and antagonizes its function</article-title><source>J Virol</source><year>2020</year><volume>94</volume><fpage>e01280-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.01280-19</pub-id><pub-id pub-id-type="pmid">31723026</pub-id><pub-id pub-id-type="pmcid">PMC7000985</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dandachi</surname><given-names>D</given-names></name><name name-style="western"><surname>Mor&#243;n</surname><given-names>F</given-names></name></person-group><article-title>Effects of HIV on the tumor microenvironment</article-title><source>Adv Exp Med Biol</source><year>2020</year><volume>1263</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/978-3-030-44518-8_4</pub-id><pub-id pub-id-type="pmid">32588322</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name></person-group><article-title>Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus: role of JAK/STAT signaling</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>2401</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1128/JVI.02024-06</pub-id><pub-id pub-id-type="pmid">17151125</pub-id><pub-id pub-id-type="pmcid">PMC1865948</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>F</given-names></name><name name-style="western"><surname>Xue</surname><given-names>M</given-names></name><name name-style="western"><surname>Qin</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Hao</surname><given-names>T</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Z</given-names></name><name name-style="western"><surname>Feng</surname><given-names>N</given-names></name><name name-style="western"><surname>Gao</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Chun</surname><given-names>LuC</given-names></name></person-group><article-title>HIV-1 Tat promotes Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K/PTEN/AKT/GSK-3&#946; signaling pathway</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e53145</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0053145</pub-id><pub-id pub-id-type="pmid">23301033</pub-id><pub-id pub-id-type="pmcid">PMC3534639</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Longworth</surname><given-names>MS</given-names></name><name name-style="western"><surname>Laimins</surname><given-names>LA</given-names></name></person-group><article-title>Pathogenesis of human papillomaviruses in differentiating epithelia</article-title><source>Microbiol Mol Biol Rev</source><year>2004</year><volume>68</volume><fpage>362</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1128/MMBR.68.2.362-372.2004</pub-id><pub-id pub-id-type="pmid">15187189</pub-id><pub-id pub-id-type="pmcid">PMC419925</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tornesello</surname><given-names>ML</given-names></name><name name-style="western"><surname>Buonaguro</surname><given-names>FM</given-names></name><name name-style="western"><surname>Beth-Giraldo</surname><given-names>E</given-names></name><name name-style="western"><surname>Giraldo</surname><given-names>G</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression</article-title><source>Intervirology</source><year>1993</year><volume>36</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1159/000150322</pub-id><pub-id pub-id-type="pmid">8294182</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyagol</surname><given-names>J</given-names></name><name name-style="western"><surname>Leucci</surname><given-names>E</given-names></name><name name-style="western"><surname>Onnis</surname><given-names>A</given-names></name><name name-style="western"><surname>De Falco</surname><given-names>G</given-names></name><name name-style="western"><surname>Tigli</surname><given-names>C</given-names></name><name name-style="western"><surname>Sanseverino</surname><given-names>F</given-names></name><name name-style="western"><surname>Torriccelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Palummo</surname><given-names>N</given-names></name><name name-style="western"><surname>Pacenti</surname><given-names>L</given-names></name><name name-style="western"><surname>Santopietro</surname><given-names>R</given-names></name><name name-style="western"><surname>Spina</surname><given-names>D</given-names></name><name name-style="western"><surname>Gichangi</surname><given-names>P</given-names></name><name name-style="western"><surname>Muchiri</surname><given-names>L</given-names></name><name name-style="western"><surname>Lazzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Petraglia</surname><given-names>F</given-names></name><name name-style="western"><surname>Leoncini</surname><given-names>L</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>A</given-names></name></person-group><article-title>The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis</article-title><source>Cancer Biol Ther</source><year>2006</year><volume>5</volume><fpage>684</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.4161/cbt.5.6.2907</pub-id><pub-id pub-id-type="pmid">16855377</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tugizov</surname><given-names>SM</given-names></name><name name-style="western"><surname>Herrera</surname><given-names>R</given-names></name><name name-style="western"><surname>Chin-Hong</surname><given-names>P</given-names></name><name name-style="western"><surname>Veluppillai</surname><given-names>P</given-names></name><name name-style="western"><surname>Greenspan</surname><given-names>D</given-names></name><name name-style="western"><surname>Berry</surname><given-names>JM</given-names></name><name name-style="western"><surname>Pilcher</surname><given-names>CD</given-names></name><name name-style="western"><surname>Shiboski</surname><given-names>CH</given-names></name><name name-style="western"><surname>Jay</surname><given-names>N</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>M</given-names></name><name name-style="western"><surname>Chein</surname><given-names>A</given-names></name><name name-style="western"><surname>Joel</surname><given-names>M</given-names></name></person-group><article-title>HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus</article-title><source>Virology</source><year>2013</year><volume>446</volume><fpage>378</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2013.08.018</pub-id><pub-id pub-id-type="pmid">24074602</pub-id><pub-id pub-id-type="pmcid">PMC3809142</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brickman</surname><given-names>C</given-names></name><name name-style="western"><surname>Palefsky</surname><given-names>JM</given-names></name></person-group><article-title>Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era</article-title><source>Curr HIV/AIDS Rep</source><year>2015</year><volume>12</volume><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s11904-014-0254-4</pub-id><pub-id pub-id-type="pmid">25644977</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barillari</surname><given-names>G</given-names></name><name name-style="western"><surname>Palladino</surname><given-names>C</given-names></name><name name-style="western"><surname>Bacigalupo</surname><given-names>I</given-names></name><name name-style="western"><surname>Leone</surname><given-names>P</given-names></name><name name-style="western"><surname>Falchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels</article-title><source>Oncol Lett</source><year>2016</year><volume>12</volume><fpage>2389</fpage><lpage>2394</lpage><pub-id pub-id-type="doi">10.3892/ol.2016.4921</pub-id><pub-id pub-id-type="pmid">27698804</pub-id><pub-id pub-id-type="pmcid">PMC5038842</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombrino</surname><given-names>E</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ballon</surname><given-names>G</given-names></name><name name-style="western"><surname>Terrin</surname><given-names>L</given-names></name><name name-style="western"><surname>Indraccolo</surname><given-names>S</given-names></name><name name-style="western"><surname>Chieco-Bianchi</surname><given-names>L</given-names></name><name name-style="western"><surname>De Rossi</surname><given-names>A</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells</article-title><source>Exp Cell Res</source><year>2004</year><volume>295</volume><fpage>539</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2004.01.018</pub-id><pub-id pub-id-type="pmid">15093750</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Germini</surname><given-names>D</given-names></name><name name-style="western"><surname>Tsfasman</surname><given-names>T</given-names></name><name name-style="western"><surname>Klibi</surname><given-names>M</given-names></name><name name-style="western"><surname>El-Amine</surname><given-names>R</given-names></name><name name-style="western"><surname>Pichugin</surname><given-names>A</given-names></name><name name-style="western"><surname>Iarovaia</surname><given-names>OV</given-names></name><name name-style="western"><surname>Bilhou-Nabera</surname><given-names>C</given-names></name><name name-style="western"><surname>Subra</surname><given-names>F</given-names></name><name name-style="western"><surname>Bou Saada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sukhanova</surname><given-names>A</given-names></name><name name-style="western"><surname>Boutboul</surname><given-names>D</given-names></name><name name-style="western"><surname>Rapha&#235;l</surname><given-names>M</given-names></name><name name-style="western"><surname>Wiels</surname><given-names>J</given-names></name><name name-style="western"><surname>Razin</surname><given-names>SV</given-names></name><name name-style="western"><surname>Bury-Mon&#233;</surname><given-names>S</given-names></name><name name-style="western"><surname>Oksenhendler</surname><given-names>E</given-names></name><name name-style="western"><surname>Lipinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Vassetzky</surname><given-names>YS</given-names></name></person-group><article-title>HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells</article-title><source>Leukemia</source><year>2017</year><volume>31</volume><fpage>2515</fpage><lpage>2522</lpage><pub-id pub-id-type="doi">10.1038/leu.2017.106</pub-id><pub-id pub-id-type="pmid">28360415</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carbone</surname><given-names>A</given-names></name><name name-style="western"><surname>Volpi</surname><given-names>CC</given-names></name><name name-style="western"><surname>Gualeni</surname><given-names>AV</given-names></name><name name-style="western"><surname>Gloghini</surname><given-names>A</given-names></name></person-group><article-title>Epstein-Barr virus associated lymphomas in people with HIV</article-title><source>Curr Opin HIV AIDS</source><year>2017</year><volume>12</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000333</pub-id><pub-id pub-id-type="pmid">27755151</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Amine</surname><given-names>R</given-names></name><name name-style="western"><surname>Germini</surname><given-names>D</given-names></name><name name-style="western"><surname>Zakharova</surname><given-names>VV</given-names></name><name name-style="western"><surname>Tsfasman</surname><given-names>T</given-names></name><name name-style="western"><surname>Sheval</surname><given-names>EV</given-names></name><name name-style="western"><surname>Louzada</surname><given-names>RAN</given-names></name><name name-style="western"><surname>Dupuy</surname><given-names>C</given-names></name><name name-style="western"><surname>Bilhou-Nabera</surname><given-names>C</given-names></name><name name-style="western"><surname>Hamade</surname><given-names>A</given-names></name><name name-style="western"><surname>Najjar</surname><given-names>F</given-names></name><name name-style="western"><surname>Oksenhendler</surname><given-names>E</given-names></name><name name-style="western"><surname>Lipinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Chernyak</surname><given-names>BV</given-names></name><name name-style="western"><surname>Vassetzky</surname><given-names>YS</given-names></name></person-group><article-title>HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production</article-title><source>Redox Biol</source><year>2018</year><volume>15</volume><fpage>97</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2017.11.024</pub-id><pub-id pub-id-type="pmid">29220699</pub-id><pub-id pub-id-type="pmcid">PMC5725280</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><mixed-citation publication-type="other">Wang X, Duan Z, Yu G, Fan M, Scharff MD (2018) Human immunodeficiency virus Tat protein aids V region somatic hypermutation in human B cells. mBio 9:e02315-17. 10.1128/mBio.02315-17<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.02315-17</pub-id><pub-id pub-id-type="pmcid">PMC5904410</pub-id><pub-id pub-id-type="pmid">29666292</pub-id></mixed-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sall</surname><given-names>FB</given-names></name><name name-style="western"><surname>El Amine</surname><given-names>R</given-names></name><name name-style="western"><surname>Markozashvili</surname><given-names>D</given-names></name><name name-style="western"><surname>Tsfasman</surname><given-names>T</given-names></name><name name-style="western"><surname>Oksenhendler</surname><given-names>E</given-names></name><name name-style="western"><surname>Lipinski</surname><given-names>M</given-names></name><name name-style="western"><surname>Vassetzky</surname><given-names>Y</given-names></name><name name-style="western"><surname>Germini</surname><given-names>D</given-names></name></person-group><article-title>HIV-1 Tat protein induces aberrant activation of AICDA in human B-lymphocytes from peripheral blood</article-title><source>J Cell Physiol</source><year>2019</year><pub-id pub-id-type="doi">10.1002/jcp.28219</pub-id><pub-id pub-id-type="pmid">30701532</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><mixed-citation publication-type="other">Duan M, Yao H, Hu G, Chen X, Lund AK, Buch S (2013) HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221/-222 in HIV-associated cardiomyopathy. PLoS One 8:e60170. 10.1371/journal.pone.0060170<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0060170</pub-id><pub-id pub-id-type="pmcid">PMC3610892</pub-id><pub-id pub-id-type="pmid">23555914</pub-id></mixed-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>T</given-names></name><name name-style="western"><surname>Yi</surname><given-names>R</given-names></name><name name-style="western"><surname>Green</surname><given-names>LA</given-names></name><name name-style="western"><surname>Chelvanambi</surname><given-names>S</given-names></name><name name-style="western"><surname>Seimetz</surname><given-names>M</given-names></name><name name-style="western"><surname>Clauss</surname><given-names>M</given-names></name></person-group><article-title>Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat</article-title><source>Cardiovasc Pathol</source><year>2015</year><volume>24</volume><fpage>279</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.carpath.2015.07.001</pub-id><pub-id pub-id-type="pmid">26233281</pub-id><pub-id pub-id-type="pmcid">PMC4831910</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chai</surname><given-names>L</given-names></name><name name-style="western"><surname>Blessing Fasae</surname><given-names>M</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y</given-names></name></person-group><article-title>The role of HIV Tat protein in HIV-related cardiovascular diseases</article-title><source>J Transl Med</source><year>2018</year><volume>16</volume><fpage>121</fpage><pub-id pub-id-type="doi">10.1186/s12967-018-1500-0</pub-id><pub-id pub-id-type="pmid">29739413</pub-id><pub-id pub-id-type="pmcid">PMC5941636</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ajasin</surname><given-names>D</given-names></name><name name-style="western"><surname>Eugenin</surname><given-names>EA</given-names></name></person-group><article-title>HIV-1 Tat: Role in Bystander Toxicity</article-title><source>Front Cell Infect Microbiol</source><year>2020</year><volume>10</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2020.00061</pub-id><pub-id pub-id-type="pmid">32158701</pub-id><pub-id pub-id-type="pmcid">PMC7052126</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doublier</surname><given-names>S</given-names></name><name name-style="western"><surname>Zennaro</surname><given-names>C</given-names></name><name name-style="western"><surname>Spatola</surname><given-names>T</given-names></name><name name-style="western"><surname>Lupia</surname><given-names>E</given-names></name><name name-style="western"><surname>Bottelli</surname><given-names>A</given-names></name><name name-style="western"><surname>Deregibus</surname><given-names>MC</given-names></name><name name-style="western"><surname>Carraro</surname><given-names>M</given-names></name><name name-style="western"><surname>Conaldi</surname><given-names>PG</given-names></name><name name-style="western"><surname>Camussi</surname><given-names>G</given-names></name></person-group><article-title>HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy</article-title><source>AIDS</source><year>2007</year><volume>21</volume><fpage>423</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e328012c522</pub-id><pub-id pub-id-type="pmid">17301560</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><mixed-citation publication-type="other">Tang P, Das JR, Li J, Yu J, Ray PE (2020) An HIV-Tat inducible mouse model system of childhood HIV-associated nephropathy. Dis Model Mech 13:dmm045641. 10.1242/dmm.045641<pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dmm.045641</pub-id><pub-id pub-id-type="pmcid">PMC7648609</pub-id><pub-id pub-id-type="pmid">32917744</pub-id></mixed-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gibellini</surname><given-names>D</given-names></name><name name-style="western"><surname>De Crignis</surname><given-names>E</given-names></name><name name-style="western"><surname>Ponti</surname><given-names>C</given-names></name><name name-style="western"><surname>Borderi</surname><given-names>M</given-names></name><name name-style="western"><surname>Cl&#242;</surname><given-names>A</given-names></name><name name-style="western"><surname>Miserocchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Viale</surname><given-names>P</given-names></name><name name-style="western"><surname>Re</surname><given-names>MC</given-names></name></person-group><article-title>HIV-1 Tat protein enhances RANKL/M-CSF-mediated osteoclast differentiation</article-title><source>Biochem Biophys Res Commun</source><year>2010</year><volume>401</volume><fpage>429</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.09.071</pub-id><pub-id pub-id-type="pmid">20869948</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chew</surname><given-names>N</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Lim</surname><given-names>R</given-names></name></person-group><article-title>HIV-1 tat and rev upregulates osteoclast bone resorption</article-title><source>J Int AIDS Soc</source><year>2014</year><volume>17</volume><fpage>19724</fpage><pub-id pub-id-type="doi">10.7448/IAS.17.4.19724</pub-id><pub-id pub-id-type="pmid">25397470</pub-id><pub-id pub-id-type="pmcid">PMC4225338</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaupere</surname><given-names>C</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>M</given-names></name><name name-style="western"><surname>Larghero</surname><given-names>J</given-names></name><name name-style="western"><surname>F&#232;ve</surname><given-names>B</given-names></name><name name-style="western"><surname>Capeau</surname><given-names>J</given-names></name><name name-style="western"><surname>Lagathu</surname><given-names>C</given-names></name></person-group><article-title>The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation</article-title><source>Aging Cell</source><year>2015</year><volume>14</volume><fpage>534</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1111/acel.12308</pub-id><pub-id pub-id-type="pmid">25847297</pub-id><pub-id pub-id-type="pmcid">PMC4531068</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berni Canani</surname><given-names>R</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>P</given-names></name><name name-style="western"><surname>Mallardo</surname><given-names>G</given-names></name><name name-style="western"><surname>Buccigrossi</surname><given-names>V</given-names></name><name name-style="western"><surname>Secondo</surname><given-names>A</given-names></name><name name-style="western"><surname>Annunziato</surname><given-names>L</given-names></name><name name-style="western"><surname>Bruzzese</surname><given-names>E</given-names></name><name name-style="western"><surname>Albano</surname><given-names>F</given-names></name><name name-style="western"><surname>Selvaggi</surname><given-names>F</given-names></name><name name-style="western"><surname>Guarino</surname><given-names>A</given-names></name></person-group><article-title>Effects of HIV-1 Tat protein on ion secretion and on cell proliferation in human intestinal epithelial cells</article-title><source>Gastroenterology</source><year>2003</year><volume>124</volume><fpage>368</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1053/gast.2003.50056</pub-id><pub-id pub-id-type="pmid">12557143</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esposito</surname><given-names>G</given-names></name><name name-style="western"><surname>Capoccia</surname><given-names>E</given-names></name><name name-style="western"><surname>Gigli</surname><given-names>S</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>M</given-names></name><name name-style="western"><surname>Bruzzese</surname><given-names>E</given-names></name><name name-style="western"><surname>D'Alessandro</surname><given-names>A</given-names></name><name name-style="western"><surname>Cirillo</surname><given-names>C</given-names></name><name name-style="western"><surname>di Cerbo</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuomo</surname><given-names>R</given-names></name><name name-style="western"><surname>Seguella</surname><given-names>L</given-names></name><name name-style="western"><surname>Steardo</surname><given-names>L</given-names></name><name name-style="western"><surname>Sarnelli</surname><given-names>G</given-names></name></person-group><article-title>HIV-1 Tat-induced diarrhea evokes an enteric glia-dependent neuroinflammatory response in the central nervous system</article-title><source>Sci Rep</source><year>2017</year><volume>10</volume><issue>7</issue><fpage>7735</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-05245-9</pub-id><pub-id pub-id-type="pmcid">PMC5552820</pub-id><pub-id pub-id-type="pmid">28798420</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarnelli</surname><given-names>G</given-names></name><name name-style="western"><surname>Seguella</surname><given-names>L</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>M</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Gigli</surname><given-names>S</given-names></name><name name-style="western"><surname>Bruzzese</surname><given-names>E</given-names></name><name name-style="western"><surname>Lattanzi</surname><given-names>R</given-names></name><name name-style="western"><surname>D'Alessandro</surname><given-names>A</given-names></name><name name-style="western"><surname>Cuomo</surname><given-names>R</given-names></name><name name-style="western"><surname>Steardo</surname><given-names>L</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>G</given-names></name></person-group><article-title>HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia</article-title><source>J Neuroinflammation</source><year>2018</year><volume>15</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s12974-018-1126-4</pub-id><pub-id pub-id-type="pmid">29573741</pub-id><pub-id pub-id-type="pmcid">PMC5866515</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mermis</surname><given-names>J</given-names></name><name name-style="western"><surname>Gu</surname><given-names>H</given-names></name><name name-style="western"><surname>Xue</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Tawfik</surname><given-names>O</given-names></name><name name-style="western"><surname>Buch</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartolome</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Brien-Ladner</surname><given-names>A</given-names></name><name name-style="western"><surname>Dhillon</surname><given-names>NK</given-names></name></person-group><article-title>Hypoxia-inducible factor-1/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling</article-title><source>Respir Res</source><year>2011</year><volume>12</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-12-103</pub-id><pub-id pub-id-type="pmid">21819559</pub-id><pub-id pub-id-type="pmcid">PMC3163194</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chinnapaiyan</surname><given-names>S</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>R</given-names></name><name name-style="western"><surname>Bala</surname><given-names>J</given-names></name><name name-style="western"><surname>Parira</surname><given-names>T</given-names></name><name name-style="western"><surname>Agudelo</surname><given-names>M</given-names></name><name name-style="western"><surname>Nair</surname><given-names>M</given-names></name><name name-style="western"><surname>Unwalla</surname><given-names>HJ</given-names></name></person-group><article-title>Cigarette smoke promotes HIV infection of primary bronchial epithelium and additively suppresses CFTR function</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>7984</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-26095-z</pub-id><pub-id pub-id-type="pmid">29789655</pub-id><pub-id pub-id-type="pmcid">PMC5964097</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cribbs</surname><given-names>SK</given-names></name><name name-style="western"><surname>Crothers</surname><given-names>K</given-names></name><name name-style="western"><surname>Morris</surname><given-names>A</given-names></name></person-group><article-title>Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation</article-title><source>Physiol Rev</source><year>2020</year><volume>100</volume><fpage>603</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1152/physrev.00039.2018</pub-id><pub-id pub-id-type="pmid">31600121</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jana</surname><given-names>M</given-names></name><name name-style="western"><surname>Dasgupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Koka</surname><given-names>S</given-names></name><name name-style="western"><surname>He</surname><given-names>J</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C</given-names></name><name name-style="western"><surname>Pahan</surname><given-names>K</given-names></name></person-group><article-title>Human immunodeficiency virus type-1 (HIV-1) Tat induces nitric oxide synthase in human astroglia</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>3912</fpage><lpage>39319</lpage><pub-id pub-id-type="doi">10.1074/jbc.M205107200</pub-id><pub-id pub-id-type="pmcid">PMC2041896</pub-id><pub-id pub-id-type="pmid">12167619</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>TA</given-names></name><name name-style="western"><surname>Avraham</surname><given-names>HK</given-names></name><name name-style="western"><surname>Koh</surname><given-names>YH</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S</given-names></name><name name-style="western"><surname>Park</surname><given-names>IW</given-names></name><name name-style="western"><surname>Avraham</surname><given-names>S</given-names></name></person-group><article-title>HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells</article-title><source>J Immunol</source><year>2003</year><volume>170</volume><fpage>2629</fpage><lpage>2637</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.5.2629</pub-id><pub-id pub-id-type="pmid">12594291</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langford</surname><given-names>D</given-names></name><name name-style="western"><surname>Oh Kim</surname><given-names>B</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Rahimain</surname><given-names>P</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>He</surname><given-names>JJ</given-names></name></person-group><article-title>Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model</article-title><source>J Neurovirol</source><year>2018</year><volume>24</volume><fpage>168</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1007/s13365-017-0598-9</pub-id><pub-id pub-id-type="pmid">29143286</pub-id><pub-id pub-id-type="pmcid">PMC6444363</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marino</surname><given-names>J</given-names></name><name name-style="western"><surname>Maubert</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mele</surname><given-names>AR</given-names></name><name name-style="western"><surname>Spector</surname><given-names>C</given-names></name><name name-style="western"><surname>Wigdahl</surname><given-names>B</given-names></name><name name-style="western"><surname>Nonnemacher</surname><given-names>MR</given-names></name></person-group><article-title>Functional impact of HIV-1 Tat on cells of the CNS and its role in HAND</article-title><source>Cell Mol Life Sci</source><year>2020</year><volume>77</volume><fpage>5079</fpage><lpage>5099</lpage><pub-id pub-id-type="doi">10.1007/s00018-020-03561-4</pub-id><pub-id pub-id-type="pmid">32577796</pub-id><pub-id pub-id-type="pmcid">PMC7674201</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Finessi</surname><given-names>V</given-names></name><name name-style="western"><surname>Sicurella</surname><given-names>M</given-names></name><name name-style="western"><surname>Rizzotto</surname><given-names>L</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Destro</surname><given-names>F</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>P</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name></person-group><article-title>The HIV-1 Tat protein induces the activation of CD8(+)T cells and affects in vivo the magnitude and kinetics of antiviral responses</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e77746</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0077746</pub-id><pub-id pub-id-type="pmid">24223723</pub-id><pub-id pub-id-type="pmcid">PMC3817196</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comandini</surname><given-names>A</given-names></name><name name-style="western"><surname>Naro</surname><given-names>C</given-names></name><name name-style="western"><surname>Adamo</surname><given-names>R</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>AN</given-names></name><name name-style="western"><surname>Lanna</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonmassar</surname><given-names>E</given-names></name><name name-style="western"><surname>Franzese</surname><given-names>O</given-names></name></person-group><article-title>Molecular mechanisms involved in HIV-1-Tat mediated inhibition of telomerase activity in human CD4(+) T lymphocytes</article-title><source>Mol Immunol</source><year>2013</year><volume>54</volume><fpage>181</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2012.12.003</pub-id><pub-id pub-id-type="pmid">23287597</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sforza</surname><given-names>F</given-names></name><name name-style="western"><surname>Nicoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Finessi</surname><given-names>V</given-names></name><name name-style="western"><surname>Reali</surname><given-names>E</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name></person-group><article-title>HIV-1 Tat affects the programming and functionality of human CD8(+) T cells by modulating the expression of T-box transcription factors</article-title><source>AIDS</source><year>2014</year><volume>28</volume><fpage>1729</fpage><lpage>1738</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000000315</pub-id><pub-id pub-id-type="pmid">24841128</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>MK</given-names></name><name name-style="western"><surname>Gorrill</surname><given-names>TS</given-names></name><name name-style="western"><surname>Kamel Khalili</surname><given-names>K</given-names></name></person-group><article-title>Reciprocal transactivation between HIV-1 and other human viruses</article-title><source>Virology</source><year>2006</year><volume>352</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2006.04.006</pub-id><pub-id pub-id-type="pmid">16725168</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Lusso</surname><given-names>P</given-names></name><name name-style="western"><surname>Schachter</surname><given-names>F</given-names></name><name name-style="western"><surname>Josephs</surname><given-names>SF</given-names></name><name name-style="western"><surname>Rappaport</surname><given-names>J</given-names></name><name name-style="western"><surname>Negro</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>RC</given-names></name><name name-style="western"><surname>Wong-Staal</surname><given-names>F</given-names></name></person-group><article-title>Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer</article-title><source>EMBO J</source><year>1989</year><volume>8</volume><issue>10</issue><fpage>3019</fpage><lpage>3027</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1989.tb08452.x</pub-id><pub-id pub-id-type="pmid">2573513</pub-id><pub-id pub-id-type="pmcid">PMC401379</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><mixed-citation publication-type="other">Wortman MJ, Krachmarov CP, Kim JH, Gordon RG, Chepenik LG, Brady JN, Gallia GL, Khalili K, Johnson EM (2000) Interaction of HIV-1 Tat with Puralpha in nuclei of human glial cells: characterization of RNA-mediated protein-protein binding. J Cell Biochem 77:65-74. 10.1002/(sici)1097-4644(20000401)77:1&lt;65::aid-jcb7&gt;3.0.co;2-u<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-4644(20000401)77:1&lt;65::aid-jcb7&gt;3.0.co;2-u</pub-id><pub-id pub-id-type="pmid">10679817</pub-id></mixed-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mischitelli</surname><given-names>M</given-names></name><name name-style="western"><surname>Fioriti</surname><given-names>D</given-names></name><name name-style="western"><surname>Videtta</surname><given-names>M</given-names></name><name name-style="western"><surname>Degener</surname><given-names>AM</given-names></name><name name-style="western"><surname>Antinori</surname><given-names>A</given-names></name><name name-style="western"><surname>Cinque</surname><given-names>P</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>A</given-names></name><name name-style="western"><surname>Pietropaolo</surname><given-names>V</given-names></name></person-group><article-title>Investigation on the role of cell transcriptional factor Sp1 and HIV-1 TAT protein in PML onset or development</article-title><source>J Cell Physiol</source><year>2005</year><volume>204</volume><fpage>913</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/jcp.20375</pub-id><pub-id pub-id-type="pmid">15828018</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schafer</surname><given-names>SL</given-names></name><name name-style="western"><surname>Vlach</surname><given-names>J</given-names></name><name name-style="western"><surname>Pitha</surname><given-names>PM</given-names></name></person-group><article-title>Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site</article-title><source>J Virol</source><year>1996</year><volume>70</volume><fpage>6937</fpage><lpage>6946</lpage><pub-id pub-id-type="doi">10.1128/JVI.70.10.6937-6946.1996</pub-id><pub-id pub-id-type="pmid">8794337</pub-id><pub-id pub-id-type="pmcid">PMC190743</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karalic</surname><given-names>D</given-names></name><name name-style="western"><surname>Lazarevic</surname><given-names>I</given-names></name><name name-style="western"><surname>Banko</surname><given-names>A</given-names></name><name name-style="western"><surname>Cupic</surname><given-names>M</given-names></name><name name-style="western"><surname>Jevtovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Jovanovic</surname><given-names>T</given-names></name></person-group><article-title>Molecular characterization of BK virus in patients infected with human immunodeficiency virus</article-title><source>Med Microbiol Immunol</source><year>2016</year><volume>205</volume><fpage>185</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/s00430-015-0439-5</pub-id><pub-id pub-id-type="pmid">26498471</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munawwar</surname><given-names>A</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name></person-group><article-title>Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression</article-title><source>J Lab Physicians</source><year>2016</year><volume>8</volume><fpage>5</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.4103/0974-2727.176228</pub-id><pub-id pub-id-type="pmid">27013807</pub-id><pub-id pub-id-type="pmcid">PMC4785766</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crowle</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ross</surname><given-names>ER</given-names></name><name name-style="western"><surname>Cohn</surname><given-names>DL</given-names></name><name name-style="western"><surname>Gilden</surname><given-names>J</given-names></name><name name-style="western"><surname>May</surname><given-names>MH</given-names></name></person-group><article-title>Comparison of the abilities of Mycobacterium avium and Mycobacterium intracellulare to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects</article-title><source>Infect Immun</source><year>1992</year><volume>60</volume><fpage>3697</fpage><lpage>3703</lpage><pub-id pub-id-type="doi">10.1128/IAI.60.9.3697-3703.1992</pub-id><pub-id pub-id-type="pmid">1500179</pub-id><pub-id pub-id-type="pmcid">PMC257379</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denis</surname><given-names>M</given-names></name></person-group><article-title>Tat protein from HIV-1 binds to Mycobacterium avium via a bacterial integrin. Effects on extracellular and intracellular growth</article-title><source>J Immunol</source><year>1994</year><volume>153</volume><fpage>2072</fpage><lpage>2081</lpage><pub-id pub-id-type="pmid">8051412</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitaura</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohara</surname><given-names>N</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>T</given-names></name></person-group><article-title>TNF-alpha-mediated activation of HIV-1 LTR in monocytoid cells by mycobacteria</article-title><source>FEMS Immunol Med Microbiol</source><year>2001</year><volume>31</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2001.tb00505.x</pub-id><pub-id pub-id-type="pmid">11549416</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toossi</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Islam</surname><given-names>N</given-names></name><name name-style="western"><surname>Teixeira-Johnson</surname><given-names>L</given-names></name><name name-style="western"><surname>Hejal</surname><given-names>R</given-names></name><name name-style="western"><surname>Aung</surname><given-names>H</given-names></name></person-group><article-title>Transactivation of human immunodeficiency virus-1 in T-cells by Mycobacterium tuberculosis-infected mononuclear phagocytes</article-title><source>J Lab Clin Med</source><year>2004</year><volume>144</volume><fpage>108</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.lab.2004.05.012</pub-id><pub-id pub-id-type="pmid">15322505</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruber</surname><given-names>A</given-names></name><name name-style="western"><surname>Lell</surname><given-names>CP</given-names></name><name name-style="western"><surname>Speth</surname><given-names>C</given-names></name><name name-style="western"><surname>Stoiber</surname><given-names>H</given-names></name><name name-style="western"><surname>Lass-Florl</surname><given-names>C</given-names></name><name name-style="western"><surname>Sonneborn</surname><given-names>A</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>JF</given-names></name><name name-style="western"><surname>Dierich</surname><given-names>MP</given-names></name><name name-style="western"><surname>W&#252;rzner</surname><given-names>R</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro</article-title><source>Immunology</source><year>2001</year><volume>104</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.2001.01328.x</pub-id><pub-id pub-id-type="pmid">11899432</pub-id><pub-id pub-id-type="pmcid">PMC1783331</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>JC</given-names></name><name name-style="western"><surname>Yim</surname><given-names>HC</given-names></name><name name-style="western"><surname>Lau</surname><given-names>ASY</given-names></name></person-group><article-title>Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection</article-title><source>AIDS</source><year>2010</year><volume>24</volume><fpage>1609</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32833ac6a0</pub-id><pub-id pub-id-type="pmid">20588103</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Knapp</surname><given-names>PE</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T</given-names></name></person-group><article-title>HIV-1 Tat regulates the expression of the dcw operon and stimulates the proliferation of bacteria</article-title><source>Microb Pathog</source><year>2016</year><volume>90</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2015.11.005</pub-id><pub-id pub-id-type="pmid">26596708</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><mixed-citation publication-type="other">de Carvalho Vivarini A, de Meirelles Santos Pereira R, Barreto-de-Souza V, Temerozo JR, Soares DC, Saraiva EM, Mattos Saliba A, Chequer Bou-Habib D, Gazos Lopes U (2015) HIV-1 Tat protein enhances the intracellular growth of Leishmania amazonensis via the ds-RNA induced protein PKR. Sci Rep 26:16777. 10.1038/srep16777<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep16777</pub-id><pub-id pub-id-type="pmcid">PMC4660360</pub-id><pub-id pub-id-type="pmid">26608746</pub-id></mixed-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hara</surname><given-names>SP</given-names></name><name name-style="western"><surname>Small</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Gajdos</surname><given-names>GB</given-names></name><name name-style="western"><surname>Badley</surname><given-names>AD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>XM</given-names></name><name name-style="western"><surname>Larusso</surname><given-names>NF</given-names></name></person-group><article-title>HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum</article-title><source>J Infect Dis</source><year>2009</year><volume>199</volume><fpage>1195</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1086/597387</pub-id><pub-id pub-id-type="pmid">19265483</pub-id><pub-id pub-id-type="pmcid">PMC2716168</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name><name name-style="western"><surname>Ferrantelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Cara</surname><given-names>A</given-names></name><name name-style="western"><surname>Titti</surname><given-names>F</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>M</given-names></name></person-group><article-title>Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env</article-title><source>Microbes Infect</source><year>2005</year><volume>7</volume><fpage>1392</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2005.07.016</pub-id><pub-id pub-id-type="pmid">16243561</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hel</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>WP</given-names></name><name name-style="western"><surname>Tryniszewska</surname><given-names>E</given-names></name><name name-style="western"><surname>Nacsa</surname><given-names>J</given-names></name><name name-style="western"><surname>Markham</surname><given-names>PD</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>MG</given-names></name><name name-style="western"><surname>Pavlakis</surname><given-names>GN</given-names></name><name name-style="western"><surname>Felber</surname><given-names>BK</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>J</given-names></name><name name-style="western"><surname>Franchini</surname><given-names>G</given-names></name></person-group><article-title>Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes</article-title><source>J Immunol</source><year>2006</year><volume>176</volume><fpage>85</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.176.1.85</pub-id><pub-id pub-id-type="pmid">16365399</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mooij</surname><given-names>P</given-names></name><name name-style="western"><surname>Nieuwenhuis</surname><given-names>IG</given-names></name><name name-style="western"><surname>Knoop</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Doms</surname><given-names>RW</given-names></name><name name-style="western"><surname>Bogers</surname><given-names>W</given-names></name><name name-style="western"><surname>Ten Haaft</surname><given-names>P</given-names></name><name name-style="western"><surname>Niphuis</surname><given-names>H</given-names></name><name name-style="western"><surname>Koornstra</surname><given-names>W</given-names></name><name name-style="western"><surname>Bieler</surname><given-names>K</given-names></name><name name-style="western"><surname>K&#246;stler</surname><given-names>J</given-names></name><name name-style="western"><surname>Morein</surname><given-names>B</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>R</given-names></name><name name-style="western"><surname>Heeney</surname><given-names>JL</given-names></name></person-group><article-title>Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>3333</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1128/jvi.78.7.3333-3342.2004</pub-id><pub-id pub-id-type="pmid">15016855</pub-id><pub-id pub-id-type="pmcid">PMC371051</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Voltan</surname><given-names>R</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B</given-names></name><name name-style="western"><surname>Davis-Warren</surname><given-names>A</given-names></name><name name-style="western"><surname>Kalyanaraman</surname><given-names>VS</given-names></name><name name-style="western"><surname>Alvord</surname><given-names>W</given-names></name></person-group><article-title>Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag</article-title><source>Virology</source><year>2005</year><volume>342</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2005.07.016</pub-id><pub-id pub-id-type="pmid">16109434</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name><name name-style="western"><surname>Cellini</surname><given-names>S</given-names></name><name name-style="western"><surname>Castaldello</surname><given-names>A</given-names></name><name name-style="western"><surname>Voltan</surname><given-names>R</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Gagliardoni</surname><given-names>F</given-names></name><name name-style="western"><surname>Fortini</surname><given-names>C</given-names></name><name name-style="western"><surname>Cofano</surname><given-names>EB</given-names></name><name name-style="western"><surname>Triulzi</surname><given-names>C</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><etal/></person-group><article-title>The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>727</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.11.040</pub-id><pub-id pub-id-type="pmid">18096278</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Fortini</surname><given-names>C</given-names></name><name name-style="western"><surname>Fabris</surname><given-names>M</given-names></name><name name-style="western"><surname>Bottoni</surname><given-names>A</given-names></name><name name-style="western"><surname>Canella</surname><given-names>A</given-names></name><name name-style="western"><surname>Bonaccorsi</surname><given-names>A</given-names></name><name name-style="western"><surname>Marastoni</surname><given-names>M</given-names></name><name name-style="western"><surname>Micheletti</surname><given-names>F</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><etal/></person-group><article-title>HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>3838</fpage><lpage>3843</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.173.6.3838</pub-id><pub-id pub-id-type="pmid">15356131</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leifert</surname><given-names>JA</given-names></name><name name-style="western"><surname>Holler</surname><given-names>PD</given-names></name><name name-style="western"><surname>Harkins</surname><given-names>S</given-names></name><name name-style="western"><surname>Kranz</surname><given-names>DM</given-names></name><name name-style="western"><surname>Whitton</surname><given-names>JL</given-names></name></person-group><article-title>The cationic region from HIV tat enhances the cell-surface expression of epitope/MHC class I complexes</article-title><source>Gene Ther</source><year>2003</year><volume>10</volume><fpage>2067</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/sj.gt.3302115</pub-id><pub-id pub-id-type="pmid">14595379</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kittiworakarn</surname><given-names>J</given-names></name><name name-style="western"><surname>Lecoq</surname><given-names>A</given-names></name><name name-style="western"><surname>Moine</surname><given-names>G</given-names></name><name name-style="western"><surname>Thai</surname><given-names>R</given-names></name><name name-style="western"><surname>Lajeunesse</surname><given-names>E</given-names></name><name name-style="western"><surname>Drevet</surname><given-names>P</given-names></name><name name-style="western"><surname>Vidaud</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#233;nez</surname><given-names>A</given-names></name><name name-style="western"><surname>L&#233;onetti</surname><given-names>M</given-names></name></person-group><article-title>HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>3105</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1074/jbc.M509899200</pub-id><pub-id pub-id-type="pmid">16321975</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sicurella</surname><given-names>M</given-names></name><name name-style="western"><surname>Nicoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Volpi</surname><given-names>I</given-names></name><name name-style="western"><surname>Berto</surname><given-names>E</given-names></name><name name-style="western"><surname>Finessi</surname><given-names>V</given-names></name><name name-style="western"><surname>Destro</surname><given-names>F</given-names></name><name name-style="western"><surname>Manservigi</surname><given-names>R</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>PC</given-names></name></person-group><article-title>An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e100844</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0100844</pub-id><pub-id pub-id-type="pmid">25033084</pub-id><pub-id pub-id-type="pmcid">PMC4102458</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Skarlis</surname><given-names>C</given-names></name><name name-style="western"><surname>Sicurella</surname><given-names>M</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>PC</given-names></name><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name></person-group><article-title>Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2216</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.03.022</pub-id><pub-id pub-id-type="pmid">27002499</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Gallerani</surname><given-names>E</given-names></name><name name-style="western"><surname>Sicurella</surname><given-names>M</given-names></name><name name-style="western"><surname>Pacifico</surname><given-names>S</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>P</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Gavioli</surname><given-names>R</given-names></name></person-group><article-title>The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation</article-title><source>Vaccines (Basel)</source><year>2020</year><volume>8</volume><fpage>274</fpage><pub-id pub-id-type="doi">10.3390/vaccines8020274</pub-id><pub-id pub-id-type="pmcid">PMC7349931</pub-id><pub-id pub-id-type="pmid">32512757</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>R</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>D</given-names></name><name name-style="western"><surname>Garg</surname><given-names>S</given-names></name><name name-style="western"><surname>Fremgen</surname><given-names>D</given-names></name><name name-style="western"><surname>Vahed</surname><given-names>H</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>PP</given-names></name><name name-style="western"><surname>Pham</surname><given-names>TT</given-names></name><name name-style="western"><surname>Hewett</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>J</given-names></name><name name-style="western"><surname>Ong</surname><given-names>N</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L</given-names></name><name name-style="western"><surname>Scarfone</surname><given-names>VM</given-names></name><name name-style="western"><surname>Nesburn</surname><given-names>AB</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>SL</given-names></name><name name-style="western"><surname>BenMohamed</surname><given-names>L</given-names></name></person-group><article-title>Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes</article-title><source>J Virol</source><year>2015</year><volume>89</volume><fpage>3776</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1128/JVI.03419-14</pub-id><pub-id pub-id-type="pmid">25609800</pub-id><pub-id pub-id-type="pmcid">PMC4403403</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>R</given-names></name><name name-style="western"><surname>Khan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>D</given-names></name><name name-style="western"><surname>Vahed</surname><given-names>H</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>PP</given-names></name><name name-style="western"><surname>Thai</surname><given-names>NT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Pham</surname><given-names>TT</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J</given-names></name><name name-style="western"><surname>Scarfone</surname><given-names>VM</given-names></name><name name-style="western"><surname>Nesburn</surname><given-names>AB</given-names></name><name name-style="western"><surname>Wechsler</surname><given-names>SL</given-names></name><name name-style="western"><surname>BenMohamed</surname><given-names>L</given-names></name></person-group><article-title>HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgenic mice against ocular herpes</article-title><source>J Immunol</source><year>2015</year><volume>194</volume><fpage>2232</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402606</pub-id><pub-id pub-id-type="pmid">25617474</pub-id><pub-id pub-id-type="pmcid">PMC4340763</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Piccaro</surname><given-names>G</given-names></name><name name-style="western"><surname>Altavilla</surname><given-names>G</given-names></name><name name-style="western"><surname>Gigantino</surname><given-names>V</given-names></name><name name-style="western"><surname>Matarese</surname><given-names>G</given-names></name><name name-style="western"><surname>Olivieri</surname><given-names>E</given-names></name><name name-style="western"><surname>Ferrantelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Palma</surname><given-names>C</given-names></name></person-group><article-title>HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology</article-title><source>BMC Infect Dis</source><year>2016</year><volume>16</volume><fpage>442</fpage><pub-id pub-id-type="doi">10.1186/s12879-016-1724-7</pub-id><pub-id pub-id-type="pmid">27549342</pub-id><pub-id pub-id-type="pmcid">PMC4994248</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezza</surname><given-names>G</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Dorrucci</surname><given-names>M</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>M</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Scoglio</surname><given-names>A</given-names></name><name name-style="western"><surname>Collacchi</surname><given-names>B</given-names></name><name name-style="western"><surname>Ruiz-Alvarez</surname><given-names>M</given-names></name><name name-style="western"><surname>Giannetto</surname><given-names>C</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><etal/></person-group><article-title>The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: Findings in a cohort of HIV-1 seroconverters</article-title><source>J Infect Dis</source><year>2005</year><volume>191</volume><fpage>1321</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1086/428909</pub-id><pub-id pub-id-type="pmid">15776379</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Re</surname><given-names>MC</given-names></name><name name-style="western"><surname>Furlini</surname><given-names>G</given-names></name><name name-style="western"><surname>Vignoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Ramazzotti</surname><given-names>E</given-names></name><name name-style="western"><surname>Roderigo</surname><given-names>G</given-names></name><name name-style="western"><surname>De Rosa</surname><given-names>V</given-names></name><name name-style="western"><surname>Zauli</surname><given-names>G</given-names></name><name name-style="western"><surname>Lolli</surname><given-names>S</given-names></name><name name-style="western"><surname>Capitani</surname><given-names>S</given-names></name><name name-style="western"><surname>La Placa</surname><given-names>M</given-names></name></person-group><article-title>Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo</article-title><source>J Acquir Immune Defic Syndr Hum Retrovirol</source><year>1995</year><volume>10</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1097/00042560-199512000-00003</pub-id><pub-id pub-id-type="pmid">7583436</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zagury</surname><given-names>JF</given-names></name><name name-style="western"><surname>Sill</surname><given-names>A</given-names></name><name name-style="western"><surname>Blattner</surname><given-names>W</given-names></name><name name-style="western"><surname>Lachgar</surname><given-names>A</given-names></name><name name-style="western"><surname>Le Buanec</surname><given-names>H</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>M</given-names></name><name name-style="western"><surname>Rappaport</surname><given-names>J</given-names></name><name name-style="western"><surname>Hendel</surname><given-names>H</given-names></name><name name-style="western"><surname>Bizzini</surname><given-names>B</given-names></name><name name-style="western"><surname>Gringeri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine</article-title><source>J Hum Virol</source><year>1998</year><volume>1</volume><fpage>282</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">10195253</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Re</surname><given-names>MC</given-names></name><name name-style="western"><surname>Vignoli</surname><given-names>M</given-names></name><name name-style="western"><surname>Furlini</surname><given-names>G</given-names></name><name name-style="western"><surname>Gibellini</surname><given-names>D</given-names></name><name name-style="western"><surname>Colangeli</surname><given-names>V</given-names></name><name name-style="western"><surname>Vitone</surname><given-names>F</given-names></name><name name-style="western"><surname>La Placa</surname><given-names>M</given-names></name></person-group><article-title>Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients</article-title><source>J Clin Virol</source><year>2001</year><volume>21</volume><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/S1386-6532(00)00189-X</pub-id><pub-id pub-id-type="pmid">11255101</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>MW</given-names></name><name name-style="western"><surname>Mirchandani</surname><given-names>J</given-names></name><name name-style="western"><surname>Duong</surname><given-names>J</given-names></name><name name-style="western"><surname>Grimaldo</surname><given-names>S</given-names></name><name name-style="western"><surname>Kocieda</surname><given-names>V</given-names></name><name name-style="western"><surname>Hendel</surname><given-names>H</given-names></name><name name-style="western"><surname>Khalili</surname><given-names>K</given-names></name><name name-style="western"><surname>Zagury</surname><given-names>JF</given-names></name><name name-style="western"><surname>Rappaport</surname><given-names>J</given-names></name></person-group><article-title>Antibodies to Tat and Vpr in the GRIV cohort: Differential association with maintenance of long-term non-progression status in HIV-1 infection</article-title><source>Biomed Pharmacother</source><year>2003</year><volume>57</volume><fpage>4</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/S0753-3322(02)00327-X</pub-id><pub-id pub-id-type="pmid">12642031</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Francavilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Paniccia</surname><given-names>G</given-names></name><name name-style="western"><surname>Arancio</surname><given-names>A</given-names></name><name name-style="western"><surname>Angarano</surname><given-names>G</given-names></name><name name-style="western"><surname>Ladisa</surname><given-names>N</given-names></name><etal/></person-group><article-title>The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study</article-title><source>Retrovirology</source><year>2014</year><volume>11</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-11-49</pub-id><pub-id pub-id-type="pmid">24961156</pub-id><pub-id pub-id-type="pmcid">PMC4087126</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Francavilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Butt&#242;</surname><given-names>S</given-names></name><name name-style="western"><surname>Titti</surname><given-names>F</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><etal/></person-group><article-title>Development of a novel AIDS vaccine: The HIV-1 transactivator of transcription protein vaccine</article-title><source>Expert Opin Biol Ther</source><year>2015</year><volume>15</volume><fpage>S13</fpage><lpage>S29</lpage><pub-id pub-id-type="doi">10.1517/14712598.2015.1021328</pub-id><pub-id pub-id-type="pmid">26096836</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Butt&#242;</surname><given-names>S</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease</article-title><source>Vaccines (Basel)</source><year>2019</year><volume>7</volume><fpage>99</fpage><pub-id pub-id-type="doi">10.3390/vaccines7030099</pub-id><pub-id pub-id-type="pmcid">PMC6789840</pub-id><pub-id pub-id-type="pmid">31454973</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>A</given-names></name><name name-style="western"><surname>Kurle</surname><given-names>S</given-names></name><name name-style="western"><surname>Shete</surname><given-names>A</given-names></name><name name-style="western"><surname>Ghate</surname><given-names>M</given-names></name><name name-style="western"><surname>Godbole</surname><given-names>S</given-names></name><name name-style="western"><surname>Madhavi</surname><given-names>V</given-names></name><name name-style="western"><surname>Kent</surname><given-names>J</given-names></name></person-group><article-title>Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00005</pub-id><pub-id pub-id-type="pmid">28154562</pub-id><pub-id pub-id-type="pmcid">PMC5243827</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Addo</surname><given-names>MM</given-names></name><name name-style="western"><surname>Altfeld</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>ES</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>RL</given-names></name><name name-style="western"><surname>Philips</surname><given-names>MN</given-names></name><name name-style="western"><surname>Habeeb</surname><given-names>K</given-names></name><name name-style="western"><surname>Khatri</surname><given-names>A</given-names></name><name name-style="western"><surname>Brander</surname><given-names>C</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>GK</given-names></name><name name-style="western"><surname>Mazzara</surname><given-names>GP</given-names></name><etal/></person-group><article-title>HIV Controller Study Collaboration. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>1781</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1073/pnas.98.4.1781</pub-id><pub-id pub-id-type="pmid">11172028</pub-id><pub-id pub-id-type="pmcid">PMC29334</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Baalen</surname><given-names>CA</given-names></name><name name-style="western"><surname>Pontesilli</surname><given-names>O</given-names></name><name name-style="western"><surname>Huisman</surname><given-names>RC</given-names></name><name name-style="western"><surname>Geretti</surname><given-names>AM</given-names></name><name name-style="western"><surname>Klein</surname><given-names>MR</given-names></name><name name-style="western"><surname>de Wolf</surname><given-names>F</given-names></name><name name-style="western"><surname>Miedema</surname><given-names>F</given-names></name><name name-style="western"><surname>Gruters</surname><given-names>RA</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS</article-title><source>J Gen Virol</source><year>1997</year><volume>78</volume><fpage>1913</fpage><lpage>1918</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-78-8-1913</pub-id><pub-id pub-id-type="pmid">9266987</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>NA</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X</given-names></name><name name-style="western"><surname>Flower</surname><given-names>DR</given-names></name><name name-style="western"><surname>Wong</surname><given-names>M</given-names></name><name name-style="western"><surname>Michor</surname><given-names>F</given-names></name><name name-style="western"><surname>Saag</surname><given-names>MS</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>BH</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>MA</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>GM</given-names></name><name name-style="western"><surname>Borrow</surname><given-names>P</given-names></name></person-group><article-title>Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response</article-title><source>J Exp Med</source><year>2004</year><volume>200</volume><fpage>1243</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1084/jem.20040511</pub-id><pub-id pub-id-type="pmid">15545352</pub-id><pub-id pub-id-type="pmcid">PMC2211924</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>J</given-names></name><name name-style="western"><surname>McNevin</surname><given-names>J</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>U</given-names></name><etal/></person-group><article-title>Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection</article-title><source>J Immunol</source><year>2003</year><volume>171</volume><fpage>3837</fpage><lpage>3846</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.171.7.3837</pub-id><pub-id pub-id-type="pmid">14500685</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Francavilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Arancio</surname><given-names>A</given-names></name><name name-style="western"><surname>Paniccia</surname><given-names>G</given-names></name><name name-style="western"><surname>Campagna</surname><given-names>M</given-names></name><name name-style="western"><surname>Pavone-Cossut</surname><given-names>MR</given-names></name><name name-style="western"><surname>Sighinolfi</surname><given-names>L</given-names></name><name name-style="western"><surname>Latini</surname><given-names>A</given-names></name><name name-style="western"><surname>Mercurio</surname><given-names>VS</given-names></name><name name-style="western"><surname>Pietro</surname><given-names>MD</given-names></name><name name-style="western"><surname>Castelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Saracino</surname><given-names>A</given-names></name><name name-style="western"><surname>Mussini</surname><given-names>C</given-names></name><name name-style="western"><surname>Perri</surname><given-names>GD</given-names></name><name name-style="western"><surname>Galli</surname><given-names>M</given-names></name><name name-style="western"><surname>Nozza</surname><given-names>S</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name></person-group><article-title>Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART</article-title><source>EBioMedicine</source><year>2021</year><volume>66</volume><fpage>103306</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103306</pub-id><pub-id pub-id-type="pmid">33839064</pub-id><pub-id pub-id-type="pmcid">PMC8105504</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Fracasso</surname><given-names>C</given-names></name><name name-style="western"><surname>Maggiorella</surname><given-names>MT</given-names></name><name name-style="western"><surname>Goletti</surname><given-names>D</given-names></name><name name-style="western"><surname>Baroncelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Pace</surname><given-names>M</given-names></name><name name-style="western"><surname>Sernicola</surname><given-names>L</given-names></name><name name-style="western"><surname>Koanga-Mogtomo</surname><given-names>ML</given-names></name><name name-style="western"><surname>Betti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine</article-title><source>Nat Med</source><year>1999</year><volume>5</volume><fpage>643</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1038/9488</pub-id><pub-id pub-id-type="pmid">10371502</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Maggiorella</surname><given-names>MT</given-names></name><name name-style="western"><surname>Baroncelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Fracasso</surname><given-names>C</given-names></name><name name-style="western"><surname>Pace</surname><given-names>M</given-names></name><name name-style="western"><surname>Borsetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Sernicola</surname><given-names>L</given-names></name><name name-style="western"><surname>Negri</surname><given-names>DR</given-names></name><name name-style="western"><surname>Ten Haaft</surname><given-names>P</given-names></name><etal/></person-group><article-title>SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine</article-title><source>J Med Primatol</source><year>2000</year><volume>29</volume><fpage>193</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0684.2000.290313.x</pub-id><pub-id pub-id-type="pmid">11085582</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Titti</surname><given-names>F</given-names></name><name name-style="western"><surname>Fracasso</surname><given-names>C</given-names></name><name name-style="western"><surname>Maggiorella</surname><given-names>MT</given-names></name><name name-style="western"><surname>Baroncelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Caputo</surname><given-names>A</given-names></name><name name-style="western"><surname>Goletti</surname><given-names>D</given-names></name><name name-style="western"><surname>Borsetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Pace</surname><given-names>M</given-names></name><name name-style="western"><surname>Fanales-Belasio</surname><given-names>E</given-names></name><etal/></person-group><article-title>Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P)</article-title><source>Vaccine</source><year>2001</year><volume>19</volume><fpage>2862</fpage><lpage>2877</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00002-0</pub-id><pub-id pub-id-type="pmid">11282197</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maggiorella</surname><given-names>MT</given-names></name><name name-style="western"><surname>Baroncelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Michelini</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fanales-Belasio</surname><given-names>E</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Sernicola</surname><given-names>L</given-names></name><name name-style="western"><surname>Cara</surname><given-names>A</given-names></name><name name-style="western"><surname>Negri</surname><given-names>DR</given-names></name><name name-style="western"><surname>Butt&#242;</surname><given-names>S</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><etal/></person-group><article-title>Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3258</fpage><lpage>3269</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.009</pub-id><pub-id pub-id-type="pmid">15308348</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borsetti</surname><given-names>A</given-names></name><name name-style="western"><surname>Baroncelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Maggiorella</surname><given-names>MT</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Fanales-Belasio</surname><given-names>E</given-names></name><name name-style="western"><surname>Sernicola</surname><given-names>L</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Macchia</surname><given-names>I</given-names></name><name name-style="western"><surname>Michelini</surname><given-names>Z</given-names></name><name name-style="western"><surname>Belli</surname><given-names>R</given-names></name><etal/></person-group><article-title>Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243)</article-title><source>Viral Immunol</source><year>2009</year><volume>22</volume><fpage>117</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1089/vim.2008.0082</pub-id><pub-id pub-id-type="pmid">19326998</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Titti</surname><given-names>F</given-names></name><name name-style="western"><surname>Maggiorella</surname><given-names>MT</given-names></name><name name-style="western"><surname>Sernicola</surname><given-names>L</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>RW</given-names></name><name name-style="western"><surname>Venzon</surname><given-names>D</given-names></name><name name-style="western"><surname>Karl</surname><given-names>JA</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>D</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><etal/></person-group><article-title>Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P</article-title><source>J Virol</source><year>2010</year><volume>84</volume><fpage>8953</fpage><lpage>8958</lpage><pub-id pub-id-type="doi">10.1128/JVI.00377-10</pub-id><pub-id pub-id-type="pmid">20554774</pub-id><pub-id pub-id-type="pmcid">PMC2919029</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demberg</surname><given-names>T</given-names></name><name name-style="western"><surname>Florese</surname><given-names>RH</given-names></name><name name-style="western"><surname>Heath</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>K</given-names></name><name name-style="western"><surname>Kalisz</surname><given-names>I</given-names></name><name name-style="western"><surname>Kalyanaraman</surname><given-names>VS</given-names></name><name name-style="western"><surname>Lee</surname><given-names>EM</given-names></name><name name-style="western"><surname>Pal</surname><given-names>R</given-names></name><name name-style="western"><surname>Venzon</surname><given-names>D</given-names></name><name name-style="western"><surname>Grant</surname><given-names>R</given-names></name><etal/></person-group><article-title>A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>3414</fpage><lpage>3427</lpage><pub-id pub-id-type="doi">10.1128/JVI.02453-06</pub-id><pub-id pub-id-type="pmid">17229693</pub-id><pub-id pub-id-type="pmcid">PMC1866031</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lakhashe</surname><given-names>SK</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Siddappa</surname><given-names>NB</given-names></name><name name-style="western"><surname>Hemashettar</surname><given-names>G</given-names></name><name name-style="western"><surname>Polacino</surname><given-names>P</given-names></name><name name-style="western"><surname>Hu</surname><given-names>SL</given-names></name><name name-style="western"><surname>Villinger</surname><given-names>F</given-names></name><name name-style="western"><surname>Else</surname><given-names>JG</given-names></name><name name-style="western"><surname>Novembre</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>JK</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>DC</given-names></name><name name-style="western"><surname>Ruprecht</surname><given-names>RM</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>RA</given-names></name></person-group><article-title>Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e22010</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0022010</pub-id><pub-id pub-id-type="pmid">21799765</pub-id><pub-id pub-id-type="pmcid">PMC3140488</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bachler</surname><given-names>BC</given-names></name><name name-style="western"><surname>Humbert</surname><given-names>M</given-names></name><name name-style="western"><surname>Palikuqi</surname><given-names>B</given-names></name><name name-style="western"><surname>Siddappa</surname><given-names>NB</given-names></name><name name-style="western"><surname>Lakhashe</surname><given-names>SK</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>RA</given-names></name><name name-style="western"><surname>Ruprecht</surname><given-names>RM</given-names></name></person-group><article-title>Novel biopanning strategy to identify epitopes associated with vaccine protection</article-title><source>J Virol</source><year>2013</year><volume>87</volume><fpage>4403</fpage><lpage>4416</lpage><pub-id pub-id-type="doi">10.1128/JVI.02888-12</pub-id><pub-id pub-id-type="pmid">23388727</pub-id><pub-id pub-id-type="pmcid">PMC3624354</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Lazzarin</surname><given-names>A</given-names></name><name name-style="western"><surname>Visintini</surname><given-names>R</given-names></name><name name-style="western"><surname>Narciso</surname><given-names>P</given-names></name><name name-style="western"><surname>Di Carlo</surname><given-names>A</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Magnani</surname><given-names>M</given-names></name><name name-style="western"><surname>Garaci</surname><given-names>E</given-names></name></person-group><article-title>The therapeutic phase I trial of the recombinant native HIV-1 Tat protein</article-title><source>AIDS</source><year>2008</year><volume>22</volume><fpage>2207</fpage><lpage>2209</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32831392d4</pub-id><pub-id pub-id-type="pmid">18832884</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Lazzarin</surname><given-names>A</given-names></name><name name-style="western"><surname>Visintini</surname><given-names>R</given-names></name><name name-style="western"><surname>Narciso</surname><given-names>P</given-names></name><name name-style="western"><surname>Di Carlo</surname><given-names>A</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><etal/></person-group><article-title>The preventive phase I trial with the HIV-1 Tat-based vaccine</article-title><source>Vaccine</source><year>2009</year><volume>28</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.10.038</pub-id><pub-id pub-id-type="pmid">19879233</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Francavilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Paniccia</surname><given-names>G</given-names></name><name name-style="western"><surname>Arancio</surname><given-names>A</given-names></name><name name-style="western"><surname>Fiorelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Scoglio</surname><given-names>A</given-names></name><name name-style="western"><surname>Collacchi</surname><given-names>B</given-names></name><name name-style="western"><surname>Campagna</surname><given-names>M</given-names></name><etal/></person-group><article-title>Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate</article-title><source>Rev Recent Clin Trials</source><year>2009</year><volume>4</volume><fpage>195</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.2174/157488709789957529</pub-id><pub-id pub-id-type="pmid">20028332</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>A</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Marcotullio</surname><given-names>S</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name></person-group><article-title>Challenges in HIV vaccine research for treatment and prevention</article-title><source>Front Immunol</source><year>2014</year><volume>5</volume><fpage>417</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00417</pub-id><pub-id pub-id-type="pmid">25250026</pub-id><pub-id pub-id-type="pmcid">PMC4157563</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Monini</surname><given-names>P</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Casabianca</surname><given-names>A</given-names></name><name name-style="western"><surname>Orlandi</surname><given-names>C</given-names></name><name name-style="western"><surname>Moretti</surname><given-names>S</given-names></name><name name-style="western"><surname>Francavilla</surname><given-names>V</given-names></name><name name-style="western"><surname>Arancio</surname><given-names>A</given-names></name><name name-style="western"><surname>Paniccia</surname><given-names>G</given-names></name><etal/></person-group><article-title>Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>233</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00233</pub-id><pub-id pub-id-type="pmid">30815001</pub-id><pub-id pub-id-type="pmcid">PMC6381398</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ensoli</surname><given-names>B</given-names></name><name name-style="western"><surname>Nchabeleng</surname><given-names>M</given-names></name><name name-style="western"><surname>Ensoli</surname><given-names>F</given-names></name><name name-style="western"><surname>Tripiciano</surname><given-names>A</given-names></name><name name-style="western"><surname>Bellino</surname><given-names>S</given-names></name><name name-style="western"><surname>Picconi</surname><given-names>O</given-names></name><name name-style="western"><surname>Sgadari</surname><given-names>C</given-names></name><name name-style="western"><surname>Longo</surname><given-names>O</given-names></name><name name-style="western"><surname>Tavoschi</surname><given-names>L</given-names></name><name name-style="western"><surname>Joffe</surname><given-names>D</given-names></name><collab>SMU-MeCRU study group</collab><etal/></person-group><article-title>HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: A randomized phase II clinical trial</article-title><source>Retrovirology</source><year>2016</year><volume>13</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1186/s12977-016-0261-1</pub-id><pub-id pub-id-type="pmid">27277839</pub-id><pub-id pub-id-type="pmcid">PMC4899930</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ros&#225;s-Umbert</surname><given-names>M</given-names></name><name name-style="western"><surname>Mothe</surname><given-names>B</given-names></name><name name-style="western"><surname>Noguera-Julian</surname><given-names>M</given-names></name><name name-style="western"><surname>Bellido</surname><given-names>R</given-names></name><name name-style="western"><surname>Puertas</surname><given-names>MC</given-names></name><name name-style="western"><surname>Carrillo</surname><given-names>J</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>C</given-names></name><name name-style="western"><surname>Perez-Alvarez</surname><given-names>N</given-names></name><name name-style="western"><surname>Cobars&#237;</surname><given-names>P</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>CE</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M</given-names></name><name name-style="western"><surname>J&#237;menez</surname><given-names>JL</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>F</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J</given-names></name><name name-style="western"><surname>Martinez-Picado</surname><given-names>J</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>R</given-names></name><name name-style="western"><surname>Brander</surname><given-names>C</given-names></name></person-group><article-title>Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><issue>9</issue><fpage>e0184929</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0184929</pub-id><pub-id pub-id-type="pmid">28953921</pub-id><pub-id pub-id-type="pmcid">PMC5617163</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharaf</surname><given-names>R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>GQ</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X</given-names></name><name name-style="western"><surname>Etemad</surname><given-names>B</given-names></name><name name-style="western"><surname>Aboukhater</surname><given-names>LM</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Brumme</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Aga</surname><given-names>E</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Namazi</surname><given-names>G</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>EP</given-names></name><name name-style="western"><surname>Gandhi</surname><given-names>RT</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Skiest</surname><given-names>D</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>DM</given-names></name><name name-style="western"><surname>Mitsuyasu</surname><given-names>R</given-names></name><name name-style="western"><surname>Volberding</surname><given-names>P</given-names></name><name name-style="western"><surname>Connick</surname><given-names>E</given-names></name><name name-style="western"><surname>Kuritzkes</surname><given-names>DR</given-names></name><name name-style="western"><surname>Lederman</surname><given-names>MM</given-names></name><name name-style="western"><surname>Yu</surname><given-names>XG</given-names></name><name name-style="western"><surname>Lichterfeld</surname><given-names>M</given-names></name><name name-style="western"><surname>Li</surname><given-names>JZ</given-names></name></person-group><article-title>HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><issue>9</issue><fpage>4074</fpage><lpage>4085</lpage><pub-id pub-id-type="doi">10.1172/JCI120549</pub-id><pub-id pub-id-type="pmid">30024859</pub-id><pub-id pub-id-type="pmcid">PMC6118642</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clumeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Hermans</surname><given-names>P</given-names></name><name name-style="western"><surname>Zagury</surname><given-names>D</given-names></name><name name-style="western"><surname>Le Buanec</surname><given-names>H</given-names></name><name name-style="western"><surname>Burny</surname><given-names>A</given-names></name><name name-style="western"><surname>Bizzini</surname><given-names>B</given-names></name><name name-style="western"><surname>Gilliam</surname><given-names>B</given-names></name><name name-style="western"><surname>Redfield</surname><given-names>R</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>R</given-names></name></person-group><article-title>Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study</article-title><source>Retrovirology</source><year>2006</year><volume>3</volume><issue>Suppl 1</issue><fpage>S15</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-3-S1-S15</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loret</surname><given-names>EP</given-names></name><name name-style="western"><surname>Darque</surname><given-names>A</given-names></name><name name-style="western"><surname>Jouve</surname><given-names>E</given-names></name><name name-style="western"><surname>Loret</surname><given-names>EA</given-names></name><name name-style="western"><surname>Nicolino-Brunet</surname><given-names>C</given-names></name><name name-style="western"><surname>Morange</surname><given-names>S</given-names></name><name name-style="western"><surname>Castanier</surname><given-names>E</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>J</given-names></name><name name-style="western"><surname>Caloustian</surname><given-names>C</given-names></name><name name-style="western"><surname>Bornet</surname><given-names>C</given-names></name><name name-style="western"><surname>Coussirou</surname><given-names>J</given-names></name><name name-style="western"><surname>Boussetta</surname><given-names>J</given-names></name><name name-style="western"><surname>Couallier</surname><given-names>V</given-names></name><name name-style="western"><surname>Blin</surname><given-names>O</given-names></name><name name-style="western"><surname>Dussol</surname><given-names>B</given-names></name><name name-style="western"><surname>Ravaux</surname><given-names>I</given-names></name></person-group><article-title>Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial</article-title><source>Retrovirology</source><year>2016</year><volume>13</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12977-016-0251-3</pub-id><pub-id pub-id-type="pmid">27036656</pub-id><pub-id pub-id-type="pmcid">PMC4818470</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruell</surname><given-names>H</given-names></name><name name-style="western"><surname>Klein</surname><given-names>F</given-names></name></person-group><article-title>Antibody-mediated prevention and treatment of HIV-1 infection</article-title><source>Retrovirology</source><year>2018</year><volume>15</volume><issue>1</issue><fpage>73</fpage><pub-id pub-id-type="doi">10.1186/s12977-018-0455-9</pub-id><pub-id pub-id-type="pmid">30445968</pub-id><pub-id pub-id-type="pmcid">PMC6240265</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brake</surname><given-names>DA</given-names></name><name name-style="western"><surname>Goudsmit</surname><given-names>J</given-names></name><name name-style="western"><surname>Krone</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Schammel</surname><given-names>P</given-names></name><name name-style="western"><surname>Appleby</surname><given-names>N</given-names></name><name name-style="western"><surname>Meloen</surname><given-names>RH</given-names></name><name name-style="western"><surname>Debouck</surname><given-names>C</given-names></name></person-group><article-title>Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1</article-title><source>J Virol</source><year>1990</year><volume>64</volume><issue>2</issue><fpage>962</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1128/JVI.64.2.962-965.1990</pub-id><pub-id pub-id-type="pmid">1688630</pub-id><pub-id pub-id-type="pmcid">PMC249199</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>E</given-names></name><name name-style="western"><surname>Hoebeke</surname><given-names>J</given-names></name><name name-style="western"><surname>Zagury</surname><given-names>D</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S</given-names></name><name name-style="western"><surname>Desgranges</surname><given-names>C</given-names></name></person-group><article-title>Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen</article-title><source>J Virol</source><year>2004</year><volume>78</volume><issue>7</issue><fpage>3792</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1128/jvi.78.7.3792-3796.2004</pub-id><pub-id pub-id-type="pmid">15016898</pub-id><pub-id pub-id-type="pmcid">PMC371091</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mediouni</surname><given-names>S</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>JD</given-names></name><name name-style="western"><surname>Pierres</surname><given-names>M</given-names></name><name name-style="western"><surname>Bole</surname><given-names>A</given-names></name><name name-style="western"><surname>Loret</surname><given-names>EP</given-names></name><name name-style="western"><surname>Baillat</surname><given-names>G</given-names></name></person-group><article-title>A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>15</issue><fpage>11942</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.319863</pub-id><pub-id pub-id-type="pmid">22362765</pub-id><pub-id pub-id-type="pmcid">PMC3320942</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>